index,title,abstract,Master Ref#,PubMed ID,Journal,Primary Author,Publication Year,Volume / Issue,Pages,Priority Journal,PubMed ID:,Full Reference:,"Study Outcome ($/QALY, $/DALY, Both):",Study Country:,Disease Classification:,Intervention Type(s):,Intervention Phrase vs. Comparator Phrase:,Target Characteristics:,Max Target Age:,Min Target Age:,Target Genders:,Review:,Time Horizon:,Discounting Rate (Costs):,Discounting Rate (QALYs):,Incremental Cost-Effectiveness Ratio (Original currency and year):,Currency Country:,Currency Year:,Incremental Cost-Effectiveness Ratio (Converted to current $USD):
14401,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,16 weeks of sofosbuvir-ribavirin vs. 12 weeks of sofosbuvir-ribavirin,Treatment-experienced noncirrhotic patients with genotype 2 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,295000,United States,2013,327739.65
14402,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,24 weeks of pegylated interferon-ribavirin vs. None,Treatment-naive cirrhotic patients with genotype 2 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,8700,United States,2013,9665.54
14403,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,12 weeks of sofosbuvir-ribavirin vs. 24 weeks of pegylated interferon-ribavirin,Treatment-naive cirrhotic patients with genotype 2 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,35500,United States,2013,39439.86
14404,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,12 weeks of sofosbuvir-ribavirin vs. None,Treatment-experienced cirrhotic patients with genotype 2 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,27884.62,United States,2013,30979.3
14405,The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection,"BACKGROUND: Chronic infection with hepatitis C virus (HCV) genotype 2 or 3 can be treated with sofosbuvir without interferon. Because sofosbuvir is costly, its benefits should be compared with the additional resources used. OBJECTIVE: To estimate the cost-effectiveness of sofosbuvir-based treatments for HCV genotype 2 or 3 infection in the United States. DESIGN: Monte Carlo simulation, including deterministic and probabilistic sensitivity analyses. DATA SOURCES: Randomized trials, observational cohorts, and national health care spending surveys. TARGET POPULATION: 8 patient types defined by HCV genotype (2 vs. 3), treatment history (naive vs. experienced), and cirrhosis status (noncirrhotic vs. cirrhotic). TIME HORIZON: Lifetime. PERSPECTIVE: Payer. INTERVENTION: Sofosbuvir-based therapies, pegylated interferon-ribavirin, and no therapy. OUTCOME MEASURES: Discounted quality-adjusted life-years (QALYs), costs, and incremental cost-effectiveness ratios (ICERs). RESULTS OF BASE-CASE ANALYSIS: The ICER of sofosbuvir-based treatment was less than $100,000 per QALY in cirrhotic patients (genotype 2 or 3 and treatment-naive or treatment-experienced) and in treatment-experienced noncirrhotic patients but was greater than $200,000 per QALY in treatment-naive noncirrhotic patients. RESULTS OF SENSITIVITY ANALYSIS: The ICER of sofosbuvir-based therapy for treatment-naive noncirrhotic patients with genotype 2 or 3 infection was less than $100,000 per QALY when the cost of sofosbuvir was reduced by approximately 40% and 60%, respectively. In probabilistic sensitivity analyses, cost-effectiveness conclusions were robust to uncertainty in treatment efficacy. LIMITATION: The analysis did not consider possible benefits of preventing HCV transmission. CONCLUSION: Sofosbuvir provides good value for money for treatment-experienced patients with HCV genotype 2 or 3 infection and those with cirrhosis. At their current cost, sofosbuvir-based regimens for treatment-naive noncirrhotic patients exceed willingness-to-pay thresholds commonly cited in the United States. PRIMARY FUNDING SOURCE: National Institute on Drug Abuse and National Institute of Allergy and Infectious Diseases.",2015-01-18420,25820703,Ann Intern Med,Benjamin P Linas,2015,162 / 9,619-29,No,25820703,"Benjamin P Linas; Devra M Barter; Jake R Morgan; Mai T Pho; Jared A Leff; Bruce R Schackman; C Robert Horsburgh; Sabrina A Assoumou; Joshua A Salomon; Milton C Weinstein; Kenneth A Freedberg; Arthur Y Kim; The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection, Ann Intern Med, 2015 May 5; 162(9):1539-3704; 619-29",QALY,United States of America,Not Stated,Not Stated,16 weeks of sofosbuvir-ribavirin vs. 12 weeks of sofosbuvir-ribavirin,Treatment-experienced cirrhotic patients with genotype 2 infection,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,27300,United States,2013,30329.8
14406,The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus,"AIMS: To assess the cost-effectiveness of dapagliflozin, a sodium-glucose co-transporter-2 (SGLT-2) inhibitor, compared with a sulfonylurea, when added to metformin for treatment of UK people with Type 2 diabetes mellitus inadequately controlled on metformin alone. METHODS: Clinical inputs sourced from a head-to-head randomized controlled trial (RCT) informed the Cardiff diabetes decision model. Risk equations developed from the United Kingdom Prospective Diabetes Study (UKPDS) were used in conjunction with the clinical inputs to predict disease progression and the incidence of micro- and macrovascular complications over a lifetime horizon. Cost and utility data were generated to present the incremental cost-effectiveness ratio (ICER) for both treatment arms, and sensitivity and scenario analyses were conducted to assess the impact of uncertainty on the final model results. RESULTS: The dapagliflozin treatment arm was associated with a mean incremental benefit of 0.467 quality-adjusted life years (QALYs) [95% confidence interval (CI): 0.420; 0.665], with an incremental cost of pound1246 (95% CI: pound613; pound1637). This resulted in an ICER point estimate of pound2671 per QALY gained. Incremental costs were shown to be insensitive to parameter variation, with only treatment-related weight change having a significant impact on the incremental QALYs. Probabilistic sensitivity analysis determined that dapagliflozin had a 100% probability of being cost-effective at a willingness-to-pay threshold of pound20,000 per QALY. CONCLUSIONS: Dapagliflozin in combination with metformin was shown to be a cost-effective treatment option compared with sulfonylurea from a UK healthcare perspective for people with Type 2 diabetes mellitus who are inadequately controlled on metformin monotherapy.",2015-01-18424,25817050,Diabet Med,M Charokopou,2015,32 / 7,890-8,No,25817050,"M Charokopou; P McEwan; S Lister; L Callan; K Bergenheim; K Tolley; R Postema; R Townsend; M Roudaut; The cost-effectiveness of dapagliflozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus, Diabet Med, 2015 Jul; 32(7):0742-3071; 890-8",QALY,United Kingdom,Not Stated,Not Stated,Dapagliflozin added to metfomin therapy vs. Sulfonylurea added to metfomin therapy,Inadequately controlled on metformin monotherapy,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.50,3.50,2671,United Kingdom,2011,4930.35
14407,Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection,"We examined the impact of antiretroviral treatment adherence among hepatitis C (HCV) coinfected human immunodeficiency virus (HIV) patients on survival and clinical outcomes. We analyzed Medicaid claims data from 14 southern states from 2005 to 2007, comparing survival and clinical outcomes and cost of treatment for HIV and HCV coinfected patients (N = 4115) at different levels of adherence to antiretroviral therapy (ART). More than one in five patients (20.5%) showed less than 50% adherence to antiretroviral treatment, but there were no racial/ethnic or gender disparities. Significant survival benefit was demonstrated at each incremental level of adherence to ART (one-year mortality ranging from 3.5% in the highest adherence group to 26.0% in the lowest). Low-adherence patients also had higher rates of hospitalization and emergency department visits. Relative to patients with high (>95%) ART adherence, those with less than 25% treatment adherence had fourfold greater risk of death (adjusted odds ratio 4.22 [95% CI: 3.03, 5.87]). Nondrug Medicaid expenditures were lower for high-adherence patients, but cost of medications drove total Medicaid expenditures higher for high-adherence patients. Cost per quality-adjusted life year (QALY) saved (relative to the <25% low-adherence group) ranged from $21,874 for increasing adherence to 25-50% to $37,229 for increasing adherence to 75-95%. Adherence to ART for patients with HIV and HCV coinfection is associated with lower adverse clinical outcomes at a Medicaid cost per QALY commensurate with other well-accepted treatment and prevention strategies. Further research is needed to identify interventions which can best achieve optimal ART adherence at a population scale.",2015-01-18428,25814041,AIDS Care,Shun Zhang,2015,27 / 7,829-35,No,25814041,"Shun Zhang; George Rust; Kathryn Cardarelli; Jesus Felizzola; Mesfin Fransua; Harold G Jr Stringer; Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection, AIDS Care, 2015; 27(7):0954-0121; 829-35",QALY,United States of America,Not Stated,Not Stated,25-50% adherent active antiretroviral therapy vs. <25% adherent active antiretroviral therapy,Hepatitis C co-infection,Not Stated,19 Years,"Female, Male",Full,1 Year,Not Stated,Not Stated,21874,United States,2013,24301.62
14408,Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection,"We examined the impact of antiretroviral treatment adherence among hepatitis C (HCV) coinfected human immunodeficiency virus (HIV) patients on survival and clinical outcomes. We analyzed Medicaid claims data from 14 southern states from 2005 to 2007, comparing survival and clinical outcomes and cost of treatment for HIV and HCV coinfected patients (N = 4115) at different levels of adherence to antiretroviral therapy (ART). More than one in five patients (20.5%) showed less than 50% adherence to antiretroviral treatment, but there were no racial/ethnic or gender disparities. Significant survival benefit was demonstrated at each incremental level of adherence to ART (one-year mortality ranging from 3.5% in the highest adherence group to 26.0% in the lowest). Low-adherence patients also had higher rates of hospitalization and emergency department visits. Relative to patients with high (>95%) ART adherence, those with less than 25% treatment adherence had fourfold greater risk of death (adjusted odds ratio 4.22 [95% CI: 3.03, 5.87]). Nondrug Medicaid expenditures were lower for high-adherence patients, but cost of medications drove total Medicaid expenditures higher for high-adherence patients. Cost per quality-adjusted life year (QALY) saved (relative to the <25% low-adherence group) ranged from $21,874 for increasing adherence to 25-50% to $37,229 for increasing adherence to 75-95%. Adherence to ART for patients with HIV and HCV coinfection is associated with lower adverse clinical outcomes at a Medicaid cost per QALY commensurate with other well-accepted treatment and prevention strategies. Further research is needed to identify interventions which can best achieve optimal ART adherence at a population scale.",2015-01-18428,25814041,AIDS Care,Shun Zhang,2015,27 / 7,829-35,No,25814041,"Shun Zhang; George Rust; Kathryn Cardarelli; Jesus Felizzola; Mesfin Fransua; Harold G Jr Stringer; Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection, AIDS Care, 2015; 27(7):0954-0121; 829-35",QALY,United States of America,Not Stated,Not Stated,50-75% adherent active antiretroviral therapy vs. <25% adherent active antiretroviral therapy,Hepatitis C co-infection,Not Stated,19 Years,"Female, Male",Full,1 Year,Not Stated,Not Stated,24653.3,United States,2013,27389.37
14409,Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection,"We examined the impact of antiretroviral treatment adherence among hepatitis C (HCV) coinfected human immunodeficiency virus (HIV) patients on survival and clinical outcomes. We analyzed Medicaid claims data from 14 southern states from 2005 to 2007, comparing survival and clinical outcomes and cost of treatment for HIV and HCV coinfected patients (N = 4115) at different levels of adherence to antiretroviral therapy (ART). More than one in five patients (20.5%) showed less than 50% adherence to antiretroviral treatment, but there were no racial/ethnic or gender disparities. Significant survival benefit was demonstrated at each incremental level of adherence to ART (one-year mortality ranging from 3.5% in the highest adherence group to 26.0% in the lowest). Low-adherence patients also had higher rates of hospitalization and emergency department visits. Relative to patients with high (>95%) ART adherence, those with less than 25% treatment adherence had fourfold greater risk of death (adjusted odds ratio 4.22 [95% CI: 3.03, 5.87]). Nondrug Medicaid expenditures were lower for high-adherence patients, but cost of medications drove total Medicaid expenditures higher for high-adherence patients. Cost per quality-adjusted life year (QALY) saved (relative to the <25% low-adherence group) ranged from $21,874 for increasing adherence to 25-50% to $37,229 for increasing adherence to 75-95%. Adherence to ART for patients with HIV and HCV coinfection is associated with lower adverse clinical outcomes at a Medicaid cost per QALY commensurate with other well-accepted treatment and prevention strategies. Further research is needed to identify interventions which can best achieve optimal ART adherence at a population scale.",2015-01-18428,25814041,AIDS Care,Shun Zhang,2015,27 / 7,829-35,No,25814041,"Shun Zhang; George Rust; Kathryn Cardarelli; Jesus Felizzola; Mesfin Fransua; Harold G Jr Stringer; Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection, AIDS Care, 2015; 27(7):0954-0121; 829-35",QALY,United States of America,Not Stated,Not Stated,75-95% adherent active antiretroviral therapy vs. <25% adherent active antiretroviral therapy,Hepatitis C co-infection,Not Stated,19 Years,"Female, Male",Full,1 Year,Not Stated,Not Stated,37229,United States,2013,41360.74
14410,Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection,"We examined the impact of antiretroviral treatment adherence among hepatitis C (HCV) coinfected human immunodeficiency virus (HIV) patients on survival and clinical outcomes. We analyzed Medicaid claims data from 14 southern states from 2005 to 2007, comparing survival and clinical outcomes and cost of treatment for HIV and HCV coinfected patients (N = 4115) at different levels of adherence to antiretroviral therapy (ART). More than one in five patients (20.5%) showed less than 50% adherence to antiretroviral treatment, but there were no racial/ethnic or gender disparities. Significant survival benefit was demonstrated at each incremental level of adherence to ART (one-year mortality ranging from 3.5% in the highest adherence group to 26.0% in the lowest). Low-adherence patients also had higher rates of hospitalization and emergency department visits. Relative to patients with high (>95%) ART adherence, those with less than 25% treatment adherence had fourfold greater risk of death (adjusted odds ratio 4.22 [95% CI: 3.03, 5.87]). Nondrug Medicaid expenditures were lower for high-adherence patients, but cost of medications drove total Medicaid expenditures higher for high-adherence patients. Cost per quality-adjusted life year (QALY) saved (relative to the <25% low-adherence group) ranged from $21,874 for increasing adherence to 25-50% to $37,229 for increasing adherence to 75-95%. Adherence to ART for patients with HIV and HCV coinfection is associated with lower adverse clinical outcomes at a Medicaid cost per QALY commensurate with other well-accepted treatment and prevention strategies. Further research is needed to identify interventions which can best achieve optimal ART adherence at a population scale.",2015-01-18428,25814041,AIDS Care,Shun Zhang,2015,27 / 7,829-35,No,25814041,"Shun Zhang; George Rust; Kathryn Cardarelli; Jesus Felizzola; Mesfin Fransua; Harold G Jr Stringer; Adherence to highly active antiretroviral therapy impact on clinical and economic outcomes for Medicaid enrollees with human immunodeficiency virus and hepatitis C coinfection, AIDS Care, 2015; 27(7):0954-0121; 829-35",QALY,United States of America,Not Stated,Not Stated,>95% adherent active antiretroviral therapy vs. <25% adherent active antiretroviral therapy,Hepatitis C co-infection,Not Stated,19 Years,"Female, Male",Full,1 Year,Not Stated,Not Stated,66455,United States,2013,73830.3
14411,The cost effectiveness of the DIEP flap relative to the muscle-sparing TRAM flap in postmastectomy breast reconstruction,"BACKGROUND: The deep inferior epigastric perforator (DIEP) flap has gained notoriety because of its proposed benefit in decreasing donor-site morbidity but has been associated with longer operative times, higher perfusion-related complications, and increased cost relative to muscle-sparing free transverse rectus abdominis myocutaneous (TRAM) flaps. The authors performed the first cost-utility analysis examining the cost effectiveness of DIEP flaps relative to muscle-sparing free TRAM flaps in women who underwent mastectomy. METHODS: A comprehensive literature review was conducted using the MED- LINE, Embase, and Cochrane library databases to include studies directly comparing DIEP to muscle-sparing free TRAM flaps in matched patient cohorts. Eight studies were included, examining 740 DIEP flaps and 807 muscle-sparing free TRAM flaps. Costs were derived adopting both societal and third-party payer perspectives. Utilities were derived from a previous cost-utility analysis. Probabilities of clinically relevant complications were combined with cost and utility estimates to fit into a decision tree analysis. RESULTS: The overall complication rates were 24.7 percent and 21.8 percent for DIEP and muscle-sparing free TRAM flaps, respectively. The authors' baseline analysis using Medicare reimbursement revealed a cost decrease of $69.42 and a clinical benefit of 0.0035 quality-adjusted life-year when performing DIEP flap surgery relative to muscle-sparing free TRAM flap surgery, yielding an incremental cost-utility ratio of -$19,834.29. When using societal costs, the incremental cost-utility ratio increased to $87,800. CONCLUSION: DIEP flaps are cost effective relative to muscle-sparing free TRAM flaps when patients are carefully selected based on perforator anatomy and surgery is performed by experienced surgeons.",2015-01-18431,25811560,Plast Reconstr Surg,Naveen M Krishnan,2015,135 / 4,948-58,No,25811560,"Naveen M Krishnan; Chad Purnell; Maurice Y Nahabedian; Gary L Freed; John F Nigriny; Joseph M Rosen; Gedge D Rosson; The cost effectiveness of the DIEP flap relative to the muscle-sparing TRAM flap in postmastectomy breast reconstruction, Plast Reconstr Surg, 2015 Apr; 135(4):0032-1052; 948-58",QALY,United States of America,Not Stated,Not Stated,Postmastectomy breast reconstruction--deep inferior epigastric perforator (DIEP) flaps surgery vs. Postmastectomy breast reconstruction--muscle-sparing free transverse rectus abdominis myocutaneous (TRAM) flaps surgery,Underwent mastectomy,Not Stated,19 Years,Female,Full,Lifetime,Not Stated,Not Stated,87800,United States,2013,97544.21
14412,Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial,"OBJECTIVES: Lung cancer accounts for a significant number of new cancer cases and deaths, with the majority of patients presenting with non-small cell lung cancer (NSCLC). Although epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors are recommended as an alternative to chemotherapy for certain patients, challenges exist for clinical utilization. The objective of this analysis was to assess the outcome and economic implications of a clinically validated serum-based proteomic test to guide treatment decisions in patients with advanced NSCLC, who are EGFR-negative or status unknown, and have progressed following at least one chemotherapy regimen. METHODS: This analysis was conducted from a US payer perspective. Clinical outcomes were evaluated over the lifetime of a patient, based on data from randomized trials and clinical studies. The clinical endpoints included treatment utilization, adverse events, survival, and a composite measure of length and quality of life, referred to as the quality-adjusted life year (QALY). Costs for testing, treatment, surveillance, and management of adverse events were analyzed based on publicly available costs of the related procedures. The economic endpoints were cumulative lifetime direct medical costs and cost per QALY gained. RESULTS: In the base case, treatment recommendation for 27.3% of the patient population changed from erlotinib to chemotherapy after using the proteomic test. Overall survival increased by 0.091 year and QALYs increased by 0.050 year. The total lifetime direct medical cost per patient decreased by $135 with test-guided treatment. The findings were robust over a wide range of variation in the input parameters. CONCLUSION: The serum-based proteomic test informed treatment selection for patients with advanced NSCLC who failed previous chemotherapy regimen(s), improving QALYs and saving costs.",2015-01-18450,25804732,Lung Cancer,John Hornberger,2015,88 / 2,223-30,No,25804732,"John Hornberger; Fred R Hirsch; Qianyi Li; Ray D Page; Outcome and economic implications of proteomic test-guided second- or third-line treatment for advanced non-small cell lung cancer: extended analysis of the PROSE trial, Lung Cancer, 2015 May; 88(2):0169-5002; 223-30",QALY,United States of America,Not Stated,Not Stated,Treatment with proteomic test vs. Treatment without proteomic test,Not Stated,Not Stated,19 Years,"Female, Male",Full,"3 Years, Lifetime",3.00,3.00,-2700,United States,2014,-2951.77
14413,Cost-effectiveness analysis of endoscopic ultrasound versus magnetic resonance cholangiopancreatography in patients with suspected common bile duct stones,"BACKGROUND: Patients with suspected common bile duct (CBD) stones are often diagnosed using endoscopic retrograde cholangiopancreatography (ERCP), an invasive procedure with risk of significant complications. Using endoscopic ultrasound (EUS) or Magnetic Resonance CholangioPancreatography (MRCP) first to detect CBD stones can reduce the risk of unnecessary procedures, cut complications and may save costs. AIM: This study sought to compare the cost-effectiveness of initial EUS or MRCP in patients with suspected CBD stones. METHODS: This study is a model based cost-utility analysis estimating mean costs and quality-adjusted life years (QALYs) per patient from the perspective of the UK National Health Service (NHS) over a 1 year time horizon. A decision tree model was constructed and populated with probabilities, outcomes and cost data from published sources, including one-way and probabilistic sensitivity analyses. RESULTS: Using MRCP to select patients for ERCP was less costly than using EUS to select patients or proceeding directly to ERCP ($1299 versus $1753 and $1781, respectively), with similar QALYs accruing to each option (0.998, 0.998 and 0.997 for EUS, MRCP and direct ERCP, respectively). Initial MRCP was the most cost-effective option with the highest monetary net benefit, and this result was not sensitive to model parameters. MRCP had a 61% probability of being cost-effective at $29,000, the maximum willingness to pay for a QALY commonly used in the UK. CONCLUSION: From the perspective of the UK NHS, MRCP was the most cost-effective test in the diagnosis of CBD stones.",2015-01-18455,25799113,PLoS One,Stephen Morris,2015,10 / 3,e0121699,No,25799113,"Stephen Morris; Kurinchi S Gurusamy; Jessica Sheringham; Brian R Davidson; Cost-effectiveness analysis of endoscopic ultrasound versus magnetic resonance cholangiopancreatography in patients with suspected common bile duct stones, PLoS One , 2015; 10(3):1932-6203; e0121699",QALY,United Kingdom,Not Stated,Not Stated,Magnetic Resonance CholangioPancreatography proceeding endoscopic retrograde cholangiopancreatography vs. Standard/Usual Care- Direct endoscopic retrograde cholangiopancreatography,Not Stated,Not Stated,19 Years,"Female, Male",Full,1 Year,Not Stated,Not Stated,-481999.97,United States,2012,-543336.91
14414,Cost-effectiveness analysis of endoscopic ultrasound versus magnetic resonance cholangiopancreatography in patients with suspected common bile duct stones,"BACKGROUND: Patients with suspected common bile duct (CBD) stones are often diagnosed using endoscopic retrograde cholangiopancreatography (ERCP), an invasive procedure with risk of significant complications. Using endoscopic ultrasound (EUS) or Magnetic Resonance CholangioPancreatography (MRCP) first to detect CBD stones can reduce the risk of unnecessary procedures, cut complications and may save costs. AIM: This study sought to compare the cost-effectiveness of initial EUS or MRCP in patients with suspected CBD stones. METHODS: This study is a model based cost-utility analysis estimating mean costs and quality-adjusted life years (QALYs) per patient from the perspective of the UK National Health Service (NHS) over a 1 year time horizon. A decision tree model was constructed and populated with probabilities, outcomes and cost data from published sources, including one-way and probabilistic sensitivity analyses. RESULTS: Using MRCP to select patients for ERCP was less costly than using EUS to select patients or proceeding directly to ERCP ($1299 versus $1753 and $1781, respectively), with similar QALYs accruing to each option (0.998, 0.998 and 0.997 for EUS, MRCP and direct ERCP, respectively). Initial MRCP was the most cost-effective option with the highest monetary net benefit, and this result was not sensitive to model parameters. MRCP had a 61% probability of being cost-effective at $29,000, the maximum willingness to pay for a QALY commonly used in the UK. CONCLUSION: From the perspective of the UK NHS, MRCP was the most cost-effective test in the diagnosis of CBD stones.",2015-01-18455,25799113,PLoS One,Stephen Morris,2015,10 / 3,e0121699,No,25799113,"Stephen Morris; Kurinchi S Gurusamy; Jessica Sheringham; Brian R Davidson; Cost-effectiveness analysis of endoscopic ultrasound versus magnetic resonance cholangiopancreatography in patients with suspected common bile duct stones, PLoS One , 2015; 10(3):1932-6203; e0121699",QALY,United Kingdom,Not Stated,Not Stated,Endoscopic ultrasound proceeding endoscopic retrograde cholangiopancreatography vs. Standard/Usual Care- Direct endoscopic retrograde cholangiopancreatography,Not Stated,Not Stated,19 Years,"Female, Male",Full,1 Year,Not Stated,Not Stated,-28000,United States,2012,-31563.14
14415,Cost effectiveness of 'on demand' HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada,"BACKGROUND: Recent trials report the efficacy of continuous tenofovir-based pre-exposure prophylaxis (PrEP) for prevention of HIV infection. The cost effectiveness of 'on demand' PrEP for non-injection drug-using men who have sex with men at high risk of HIV acquisition has not been evaluated. OBJECTIVE: To conduct an economic evaluation of the societal costs of HIV in Canada and evaluate the potential benefits of this PrEP strategy. METHODS: Direct HIV costs comprised outpatient, inpatient and emergency department costs, psychosocial costs and antiretroviral costs. Resource consumption estimates were derived from the Centre Hospitalier de l'Universite de Montreal HIV cohort. Estimates of indirect costs included employment rate and work absenteeism. Costs for 'on demand' PrEP were modelled after an ongoing clinical trial. Cost-effectiveness analysis compared costs of 'on demand' PrEP to prevent one infection with lifetime costs of one HIV infection. Benefits were presented in terms of life-years and quality-adjusted life-years. RESULTS: The average annual direct cost of one HIV infection was $16,109 in the least expensive antiretroviral regimen scenario and $24,056 in the most expensive scenario. The total indirect cost was $11,550 per year. Total costs for the first year of HIV infection ranged from $27,410 to $35,358. Undiscounted lifetime costs ranged from $1,439,984 ($662,295 discounted at 3% and $448,901 at 5%) to $1,482,502 ($690,075 at 3% and $485,806 at 5%). The annual cost of PrEP was $12,001 per participant, and $621,390 per infection prevented. The PrEP strategy was cost-saving in all scenarios for undiscounted and 3% discounting rates. At 5% discounting rates, the strategy is largely cost-effective: according to least and most expensive scenarios, incremental cost-effectiveness ratios ranged from $60,311 to $47,407 per quality-adjusted life-year. CONCLUSION: This 'on demand' PrEP strategy ranges from cost-saving to largely cost-effective. The authors believe it represents an important public health strategy for the prevention of HIV transmission.",2015-01-18458,25798150,Can J Infect Dis Med Microbiol,Estelle Ouellet,2015,26 / 1,23-9,No,25798150,"Estelle Ouellet; Madeleine Durand; Jason R Guertin; Jacques LeLorier; Cecile L Tremblay; Cost effectiveness of 'on demand' HIV pre-exposure prophylaxis for non-injection drug-using men who have sex with men in Canada, Can J Infect Dis Med Microbiol, 2015 Jan-Feb; 26(1):1712-9532; 23-9",QALY,Canada,Not Stated,Not Stated,Tenofovir-based pre-exposure prophylaxis-related strategy vs. None,"Non-injection drug-using, men who have sex with men",40 Years,19 Years,Male,Full,Lifetime,3.00,3.00,-7396.93,Canada,2012,-8340.14
14416,Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece,"The study aims to evaluate the cost-effectiveness of adding tocilizumab (TCZ) first line to a treatment sequence for patients with active rheumatoid arthritis (RA), who had an inadequate response to one or more traditional synthetic disease-modifying antirheumatic drugs (DMARDs) and are intolerant to methotrexate (MTX), or in whom continued treatment with MTX is considered inappropriate. An individual simulation model was applied to project lifetime costs and outcomes for 10,000 patients from a payer's perspective. The analysis compared the standard treatment pathway (STP) with a similar pathway, where treatment was initiated with TCZ. QALYs were used as primary efficacy outcomes. Efficacy data were obtained from the ADACTA trial and a network meta-analysis. Clinical practice standards were derived from an expert panel of Greek rheumatologists. Results indicate that a treatment sequence starting with TCZ yields 1.17 more QALYs (9.38 vs. 8.21) at an additional cost of <euro>33,744 (<euro>119,840 vs. <euro>86,096) compared with the STP. The incremental cost-effectiveness ratio was <euro>28,837/QALY gained. Probabilistic sensitivity analysis confirms robustness of these findings as consistently below a threshold of <euro>45,000. The results of the analysis suggest that TCZ, when used as a first-line biologic monotherapy, can be a cost-effective treatment option for the management of active RA in patients in need of biologic monotherapy.",2015-01-18465,25794569,Rheumatol Int,Kostas Athanasakis,2015,35 / 9,1489-95,No,25794569,"Kostas Athanasakis; Filippos Tarantilis; Konstantina Tsalapati; Thomais Konstantopoulou; Eleni Vritzali; John Kyriopoulos; Cost-utility analysis of tocilizumab monotherapy in first line versus standard of care for the treatment of rheumatoid arthritis in Greece, Rheumatol Int, 2015 Sep; 35(9):0172-8172; 1489-95",QALY,Greece,Not Stated,Not Stated,Treatment pathway initiated with tocilizumab vs. Standard/Usual Care,Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,28837,Euro,2013,42550.11
14417,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"Amsterdam, immunohistochemistry, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14418,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"Amsterdam, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14419,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"Mismatch repair predict, immunohistochemistry, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14420,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"Mismatch repair predict, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14421,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"Mismatch repair pro, immunohistochemistry, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14422,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"Mismatch repair pro, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14423,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"PREMM, immunohistochemistry, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14424,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"PREMM, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14425,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"Bethesda, immunohistochemistry, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14426,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"Bethesda, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14427,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"Imunohistochemistry, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14428,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"Immunohistochemistry + BRAF, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14429,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"Microsatellite instability, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14430,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"Microsatellite instability + immunohistochemistry, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14431,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"Microsatellite instability + immunohistochemistry + BRAF, germline vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14432,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,Up-front germline vs. None,Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14433,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"PREMM screening 1, germline age > 20 year vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14434,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"PREMM screening 2, germline age > 25 year vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14435,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"PREMM screening 3, germline age > 30 year vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14436,Comparative effectiveness of screening strategies for Lynch syndrome,"BACKGROUND: Colorectal cancer is the second leading cause of cancer death in the United States. Approximately 3% of colorectal cancers are associated with Lynch Syndrome. Controversy exists regarding the optimal screening strategy for Lynch Syndrome. METHODS: Using an individual level microsimulation of a population affected by Lynch syndrome over several years, effectiveness and cost-effectiveness of 21 screening strategies were compared. Modeling assumptions were based upon published literature, and sensitivity analyses were performed for key assumptions. In a two-step process, the number of Lynch syndrome diagnoses (Step 1) and life-years gained as a result of foreknowledge of Lynch syndrome in otherwise healthy carriers (Step 2) were measured. RESULTS: The optimal strategy was sequential screening for probands starting with a predictive model, then immunohistochemistry for mismatch repair protein expression (IHC), followed by germline mutation testing (incremental cost-effectiveness ratio [ICER] of $35 143 per life-year gained). The strategies of IHC + BRAF, germline testing and universal germline testing of colon cancer probands had ICERs of $144 117 and $996 878, respectively. CONCLUSIONS: This analysis suggests that the initial step in screening for Lynch Syndrome should be the use of predictive models in probands. Universal tumor testing and general population screening strategies are not cost-effective. When family history is unavailable, alternate strategies are appropriate. Documentation of family history and screening for Lynch Syndrome using a predictive model may be considered a quality-of-care measure for patients with colorectal cancer.",2015-01-18466,25794514,J Natl Cancer Inst,Afsaneh Barzi,2015,107 / 4,,No,25794514,"Afsaneh Barzi; Sarmad Sadeghi; Michael W Kattan; Neal J Meropol; Comparative effectiveness of screening strategies for Lynch syndrome, J Natl Cancer Inst, 2015 Apr; 107(4):0027-8874",QALY,United States of America,Not Stated,Not Stated,"PREMM screening 4, germline age > 35 year vs. None",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,Not Stated,Not Stated,Not Stated,United States,2013,Not Stated
14437,Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK,"OBJECTIVE: To evaluate the cost-effectiveness of adding bedaquiline to a background regimen (BR) of drugs for multidrug-resistant tuberculosis (MDR-TB) in the United Kingdom (UK). METHODS: A cohort-based Markov model was developed to estimate the incremental cost-effectiveness ratio of bedaquiline plus BR (BBR) versus BR alone (BR) in the treatment of MDR-TB, over a 10-year time horizon. A National Health Service (NHS) and personal social services perspective was considered. Cost-effectiveness was evaluated in terms of Quality-Adjusted Life Years (QALYs) and Disability-Adjusted Life Years (DALYs). Data were sourced from a phase II, placebo-controlled trial, NHS reference costs, and the literature; the US list price of bedaquiline was used and converted to pounds ( pound18,800). Costs and effectiveness were discounted at a rate of 3.5% per annum. Probabilistic and deterministic sensitivity analysis was conducted. RESULTS: The total discounted cost per patient (pp) on BBR was pound106,487, compared with pound117,922 for BR. The total discounted QALYs pp were 5.16 for BBR and 4.01 for BR. The addition of bedaquiline to a BR resulted in a cost-saving of pound11,434 and an additional 1.14 QALYs pp over a 10-year period, and is therefore considered to be the dominant (less costly and more effective) strategy over BR. BBR remained dominant in the majority of sensitivity analyses, with a 81% probability of being dominant versus BR in the probabilistic analysis. CONCLUSIONS: In the UK, bedaquiline is likely to be cost-effective and cost-saving, compared with the current MDR-TB standard of care under a range of scenarios. Cost-savings over a 10-year period were realized from reductions in length of hospitalization, which offset the bedaquiline drug costs. The cost-benefit conclusions held after several sensitivity analyses, thus validating assumptions made, and suggesting that the results would hold even if the actual price of bedaquiline in the UK were higher than in the US.",2015-01-18467,25794045,PLoS One,Lara J Wolfson,2015,10 / 3,e0120763,No,25794045,"Lara J Wolfson; Anna Walker; Robert Hettle; Xiaoyan Lu; Chrispin Kambili; Andrew Murungi; Gerhart Knerer; Cost-effectiveness of adding bedaquiline to drug regimens for the treatment of multidrug-resistant tuberculosis in the UK, PLoS One , 2015; 10(3):1932-6203; e0120763",QALY,United Kingdom,Not Stated,Not Stated,Bedaquiline + background regimen vs. Background regimen,Not Stated,Not Stated,19 Years,"Female, Male",Full,"10 Years, 2 years",3.50,3.50,-9943.48,United Kingdom,2013,-17279.41
14438,Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer,"BACKGROUND: The combination of nab-paclitaxel plus gemcitabine (NAB-P+GEM) has shown superior efficacy over GEM monotherapy in metastatic pancreas cancer (MPC). Independent cost-effectiveness/utility analyses of NAB-P+GEM from the payer perspective have not been conducted for the UK. METHODS: A Markov model simulating the health outcomes and total costs was developed to estimate the life years gained (LYG) and quality-adjusted life years gained (QALY) and incremental cost-effectiveness (ICER) and cost-utility ratios (ICUR) for patients with MPC in a base case and in a probabilistic (PSA) sensitivity analysis. Total cost included the cost of supportive care medications, administration, chemotherapy, disease monitoring, and adverse reactions; and was discounted at 3.5% per year. A full lifetime horizon and third party payer perspective was chosen. RESULTS: The total cost of NAB-P+GEM was pound5466 higher than the cost for GEM. Respectively, LYGs were 0.97 vs 0.79 and QALYs were 0.52 vs 0.45, with ICER of pound30 367/LYG and ICUR of pound78 086/QALY, confirmed by PSA. CONCLUSIONS: The superior survival efficacy of NAB-P+GEM over GEM in the management of MPC is associated with positive cost-effectiveness and cost-utility.",2015-01-18471,25791875,Br J Cancer,M Gharaibeh,2015,112 / 8,1301-5,No,25791875,"M Gharaibeh; A McBride; J L Bootman; I Abraham; Economic evaluation for the UK of nab-paclitaxel plus gemcitabine in the treatment of metastatic pancreas cancer, Br J Cancer, 2015 Apr 14; 112(8):0007-0920; 1301-5",QALY,United Kingdom,Not Stated,Not Stated,"Combination of nab-paclitaxel plus gemcitabine, dosed according to body surface area vs. Standard/Usual Care- Gemcitabine monotherapy, dosed according to body surface area",Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.50,3.50,78086,United Kingdom,2013,135694.95
14439,Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal,"BACKGROUND: Statin monotherapy is the mainstay of low-density lipoprotein cholesterol (LDL-C) management for high cardiovascular risk patients in Portugal; however, several therapeutic options are available and predicted to have different clinical and economic impacts. The aim of this study was to evaluate the cost-effectiveness of adding ezetimibe 10 mg (EZ10) to atorvastatin 10 or 20 mg (A10/20) vs switching to rosuvastatin 10 or 20 mg (R10/20) in Portuguese patients with coronary heart disease (CHD) and/or diabetes who are currently above the LDL-C goal. METHODS: A Markov model was used to describe CHD disease progression and the lifetime costs and utilities associated with each disease state were used to estimate the gains in life-years and quality-adjusted life-years (QALYs), as well as the incremental cost-effectiveness ratio (ICER), of the two treatment regimens. Model inputs, such as age, gender, and prevalence of cardiovascular risk factors of the dyslipidemic Portuguese patients were obtained from the Portuguese cohort of the Dyslipidemia International Study (DYSIS). The efficacy of each treatment regimen, the cost of drugs and of treating CHD events, and the utilities for each disease state were derived from published sources. RESULTS: The estimated lifetime discounted number of QALYs gained by patients treated with A10/20 was 8.70, while in those switching to R10/20 it was 8.81 and in those adding EZ10 it was 8.93. Discounted total health costs were estimated to be euro11,131 for A10/20, but euro14,511 and euro16,571 for R10/20 and A10/20 + EZ10, respectively. The ICER of adding ezetimibe vs switching to rosuvastatin was euro16,465/QALY. Based on the Portuguese cost-effectiveness willingness-to-pay threshold of euro30,000/QALY, adding ezetimibe vs switching to rosuvastatin would be a cost-effective use of resources in Portugal. Sensitivity analyses in patients with differing clinical histories (CHD or diabetes or both) yielded similar values, with no ICER over euro30,000/QALY. CONCLUSIONS: From the perspective of the National Health Service, prescribing ezetimibe to high cardiovascular risk patients being treated with atorvastatin vs switching them to rosuvastatin is projected to be a cost-effective use of resources in Portugal.",2015-01-18474,25788039,Eur J Public Health,Pedro A Laires,2015,/,1-8,No,25788039,"Pedro A Laires; Flavia Ejzykowicz; Tun-Ying Hsu; Baishali Ambegaonkar; Glenn Davies; Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal, Eur J Public Health, 2015 Sep 21; ():1464-360X; 1-8",QALY,Portugal,Not Stated,Not Stated,Atorvastatin 10 mg or 20 mg + Ezetimibe 10 mg vs. Rosuvastatin 10 mg or 20 mg,Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,5.00,5.00,16465,Euro,2013,24294.75
14440,"Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study","Gemcitabine (GEM) alone, S-1 alone and gemcitabine plus S-1 (GS) have shown a marginal clinical benefit for the treatment of advanced pancreatic cancer. However, there is no clearly defined optimal cost-effectiveness treatment. The objective of this study was to assess the cost-effectiveness of GEM alone, S-1 alone and GS for the treatment of advanced pancreatic cancer based on GEST study for public payers. A decision model compared GEM alone, S-1 alone and GS. Primary base case data were identified using the GEST study and the literatures. Costs were estimated from West China Hospital, Sichuan University, China, and incremental cost-effectiveness ratios (ICERs) were calculated. Survival benefits were reported in quality-adjusted life-months (QALMs). Sensitive analyses were performed by varying potentially modifiable parameters of the model. The base case analysis showed that the GEM cost $21,912 and yielded survival of 6.93 QALMs, S-1 cost $19,371 and yielded survival of 7.90 QALMs and GS cost $22,943 and yielded survival of 7.46 QALMs in the entire treatment. The one-way sensitivity analyses showed that the ICER of S-1 was driven mostly by the S-1 group utility score of stable state compared with GEM, and the GEM group utility score of progressed state played a key role on the ICER of GS compared with GEM. S-1 represents an attractive cost-effective treatment for advanced pancreatic cancer, given the favorable cost per QALM and improvement in clinical efficacy, especially the limited available treatment options.",2015-01-18475,25788034,Med Oncol,Jing Zhou,2015,32 / 4,121,No,25788034,"Jing Zhou; Rongce Zhao; Feng Wen; Pengfei Zhang; Ruilei Tang; Zedong Du; Xiaofeng He; Jian Zhang; Qiu Li; Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study, Med Oncol, 2015 Apr; 32(4):1559-131X; 121",QALY,China,Not Stated,Not Stated,"Gemcitabine 1000 mg/m2, intravenously on days 1 and 8 + S-1, orally, twice daily vs. Standard/Usual Care- Gemcitabine 1000 mg/m2 , intravenously, in a 30 min on days 1, 8 and 15 every 4 weeks.",Naive to chemotherapy,Not Stated,21 Years,"Female, Male",Full,Lifetime,3.00,3.00,23955.43,United States,2013,26614.05
14441,"Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study","Gemcitabine (GEM) alone, S-1 alone and gemcitabine plus S-1 (GS) have shown a marginal clinical benefit for the treatment of advanced pancreatic cancer. However, there is no clearly defined optimal cost-effectiveness treatment. The objective of this study was to assess the cost-effectiveness of GEM alone, S-1 alone and GS for the treatment of advanced pancreatic cancer based on GEST study for public payers. A decision model compared GEM alone, S-1 alone and GS. Primary base case data were identified using the GEST study and the literatures. Costs were estimated from West China Hospital, Sichuan University, China, and incremental cost-effectiveness ratios (ICERs) were calculated. Survival benefits were reported in quality-adjusted life-months (QALMs). Sensitive analyses were performed by varying potentially modifiable parameters of the model. The base case analysis showed that the GEM cost $21,912 and yielded survival of 6.93 QALMs, S-1 cost $19,371 and yielded survival of 7.90 QALMs and GS cost $22,943 and yielded survival of 7.46 QALMs in the entire treatment. The one-way sensitivity analyses showed that the ICER of S-1 was driven mostly by the S-1 group utility score of stable state compared with GEM, and the GEM group utility score of progressed state played a key role on the ICER of GS compared with GEM. S-1 represents an attractive cost-effective treatment for advanced pancreatic cancer, given the favorable cost per QALM and improvement in clinical efficacy, especially the limited available treatment options.",2015-01-18475,25788034,Med Oncol,Jing Zhou,2015,32 / 4,121,No,25788034,"Jing Zhou; Rongce Zhao; Feng Wen; Pengfei Zhang; Ruilei Tang; Zedong Du; Xiaofeng He; Jian Zhang; Qiu Li; Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study, Med Oncol, 2015 Apr; 32(4):1559-131X; 121",QALY,China,Not Stated,Not Stated,"Gemcitabine 1000 mg/m2, intravenously on days 1 and 8 + S-1, orally, twice daily vs. S-1, orally, twice daily at a dose based on the body surface area",Naive to chemotherapy,Not Stated,21 Years,"Female, Male",Full,Lifetime,3.00,3.00,-97515.7,United States,2013,-108338.17
14442,"Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study","Gemcitabine (GEM) alone, S-1 alone and gemcitabine plus S-1 (GS) have shown a marginal clinical benefit for the treatment of advanced pancreatic cancer. However, there is no clearly defined optimal cost-effectiveness treatment. The objective of this study was to assess the cost-effectiveness of GEM alone, S-1 alone and GS for the treatment of advanced pancreatic cancer based on GEST study for public payers. A decision model compared GEM alone, S-1 alone and GS. Primary base case data were identified using the GEST study and the literatures. Costs were estimated from West China Hospital, Sichuan University, China, and incremental cost-effectiveness ratios (ICERs) were calculated. Survival benefits were reported in quality-adjusted life-months (QALMs). Sensitive analyses were performed by varying potentially modifiable parameters of the model. The base case analysis showed that the GEM cost $21,912 and yielded survival of 6.93 QALMs, S-1 cost $19,371 and yielded survival of 7.90 QALMs and GS cost $22,943 and yielded survival of 7.46 QALMs in the entire treatment. The one-way sensitivity analyses showed that the ICER of S-1 was driven mostly by the S-1 group utility score of stable state compared with GEM, and the GEM group utility score of progressed state played a key role on the ICER of GS compared with GEM. S-1 represents an attractive cost-effective treatment for advanced pancreatic cancer, given the favorable cost per QALM and improvement in clinical efficacy, especially the limited available treatment options.",2015-01-18475,25788034,Med Oncol,Jing Zhou,2015,32 / 4,121,No,25788034,"Jing Zhou; Rongce Zhao; Feng Wen; Pengfei Zhang; Ruilei Tang; Zedong Du; Xiaofeng He; Jian Zhang; Qiu Li; Cost-effectiveness analysis of gemcitabine, S-1 and gemcitabine plus S-1 for treatment of advanced pancreatic cancer based on GEST study, Med Oncol, 2015 Apr; 32(4):1559-131X; 121",QALY,China,Not Stated,Not Stated,"S-1, orally, twice daily at a dose based on the body surface area vs. Standard/Usual Care- Gemcitabine 1000 mg/m2 , intravenously, in a 30 min on days 1, 8 and 15 every 4 weeks.",Naive to chemotherapy,Not Stated,21 Years,"Female, Male",Full,Lifetime,3.00,3.00,-31435.18,United States,2013,-34923.91
14443,Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA),"BACKGROUND: The Multi-Ethnic Study of Atherosclerosis (MESA) showed that the addition of coronary artery calcium (CAC) to traditional risk factors improves risk classification, particularly in intermediate risk asymptomatic patients with LDL cholesterol levels <160 mg/dL. However, the cost-effectiveness of incorporating CAC into treatment decision rules has yet to be clearly delineated. OBJECTIVE: To model the cost-effectiveness of CAC for cardiovascular risk stratification in asymptomatic, intermediate risk patients not taking a statin. Treatment based on CAC was compared to (1) treatment of all intermediate-risk patients, and (2) treatment on the basis of United States guidelines. METHODS: We developed a Markov model of first coronary heart disease (CHD) and cardiovascular disease (CVD) events. We modeled statin treatment in intermediate risk patients with CAC>/=1 and CAC>/=100, with different intensities of statins based on the CAC score. We compared these CAC-based treatment strategies to a ""treat all"" strategy and to treatment according to the Adult Treatment Panel III (ATP III) guidelines. Clinical and economic outcomes were modeled over both five- and ten-year time horizons. Outcomes consisted of CHD and CVD events and Quality-Adjusted Life Years (QALYs). Sensitivity analyses considered the effect of higher event rates, different CAC and statin costs, indirect costs, and re-scanning patients with incidentalomas. RESULTS: We project that it is both cost-saving and more effective to scan intermediate-risk patients for CAC and to treat those with CAC>/=1, compared to treatment based on established risk-assessment guidelines. Treating patients with CAC>/=100 is also preferred to existing guidelines when we account for statin side effects and the disutility of statin use. CONCLUSION: Compared to the alternatives we assessed, CAC testing is both effective and cost saving as a risk-stratification tool, particularly if there are adverse effects of long-term statin use. CAC may enable providers to better tailor preventive therapy to patients' risks of CVD.",2015-01-18478,25786208,PLoS One,Eric T Roberts,2015,10 / 3,e0116377,No,25786208,"Eric T Roberts; Aaron Horne; Seth S Martin; Michael J Blaha; Ron Blankstein; Matthew J Budoff; Christopher Sibley; Joseph F Polak; Kevin D Frick; Roger S Blumenthal; Khurram Nasir; Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA), PLoS One , 2015; 10(3):1932-6203; e0116377",QALY,United States of America,Not Stated,Not Stated,Adding coronary artery calcium to traditional risk factors in coronary heart disease risk classification vs. Standard/Usual Care- Using Adult Treatment Panel III guidelines in coronary heart disease risk classification,Not Stated,Not Stated,19 Years,"Female, Male",Full,"5 Years, 10 years",3.00,3.00,Not Stated,United States,2011,Not Stated
14444,Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA),"BACKGROUND: The Multi-Ethnic Study of Atherosclerosis (MESA) showed that the addition of coronary artery calcium (CAC) to traditional risk factors improves risk classification, particularly in intermediate risk asymptomatic patients with LDL cholesterol levels <160 mg/dL. However, the cost-effectiveness of incorporating CAC into treatment decision rules has yet to be clearly delineated. OBJECTIVE: To model the cost-effectiveness of CAC for cardiovascular risk stratification in asymptomatic, intermediate risk patients not taking a statin. Treatment based on CAC was compared to (1) treatment of all intermediate-risk patients, and (2) treatment on the basis of United States guidelines. METHODS: We developed a Markov model of first coronary heart disease (CHD) and cardiovascular disease (CVD) events. We modeled statin treatment in intermediate risk patients with CAC>/=1 and CAC>/=100, with different intensities of statins based on the CAC score. We compared these CAC-based treatment strategies to a ""treat all"" strategy and to treatment according to the Adult Treatment Panel III (ATP III) guidelines. Clinical and economic outcomes were modeled over both five- and ten-year time horizons. Outcomes consisted of CHD and CVD events and Quality-Adjusted Life Years (QALYs). Sensitivity analyses considered the effect of higher event rates, different CAC and statin costs, indirect costs, and re-scanning patients with incidentalomas. RESULTS: We project that it is both cost-saving and more effective to scan intermediate-risk patients for CAC and to treat those with CAC>/=1, compared to treatment based on established risk-assessment guidelines. Treating patients with CAC>/=100 is also preferred to existing guidelines when we account for statin side effects and the disutility of statin use. CONCLUSION: Compared to the alternatives we assessed, CAC testing is both effective and cost saving as a risk-stratification tool, particularly if there are adverse effects of long-term statin use. CAC may enable providers to better tailor preventive therapy to patients' risks of CVD.",2015-01-18478,25786208,PLoS One,Eric T Roberts,2015,10 / 3,e0116377,No,25786208,"Eric T Roberts; Aaron Horne; Seth S Martin; Michael J Blaha; Ron Blankstein; Matthew J Budoff; Christopher Sibley; Joseph F Polak; Kevin D Frick; Roger S Blumenthal; Khurram Nasir; Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA), PLoS One , 2015; 10(3):1932-6203; e0116377",QALY,United States of America,Not Stated,Not Stated,Adding coronary artery calcium to traditional risk factors in coronary heart disease risk classification vs. Treat all coronary heart disease without risk classification,Not Stated,Not Stated,19 Years,"Female, Male",Full,"5 Years, 10 years",3.00,3.00,Not Stated,United States,2011,Not Stated
14445,Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA),"BACKGROUND: The Multi-Ethnic Study of Atherosclerosis (MESA) showed that the addition of coronary artery calcium (CAC) to traditional risk factors improves risk classification, particularly in intermediate risk asymptomatic patients with LDL cholesterol levels <160 mg/dL. However, the cost-effectiveness of incorporating CAC into treatment decision rules has yet to be clearly delineated. OBJECTIVE: To model the cost-effectiveness of CAC for cardiovascular risk stratification in asymptomatic, intermediate risk patients not taking a statin. Treatment based on CAC was compared to (1) treatment of all intermediate-risk patients, and (2) treatment on the basis of United States guidelines. METHODS: We developed a Markov model of first coronary heart disease (CHD) and cardiovascular disease (CVD) events. We modeled statin treatment in intermediate risk patients with CAC>/=1 and CAC>/=100, with different intensities of statins based on the CAC score. We compared these CAC-based treatment strategies to a ""treat all"" strategy and to treatment according to the Adult Treatment Panel III (ATP III) guidelines. Clinical and economic outcomes were modeled over both five- and ten-year time horizons. Outcomes consisted of CHD and CVD events and Quality-Adjusted Life Years (QALYs). Sensitivity analyses considered the effect of higher event rates, different CAC and statin costs, indirect costs, and re-scanning patients with incidentalomas. RESULTS: We project that it is both cost-saving and more effective to scan intermediate-risk patients for CAC and to treat those with CAC>/=1, compared to treatment based on established risk-assessment guidelines. Treating patients with CAC>/=100 is also preferred to existing guidelines when we account for statin side effects and the disutility of statin use. CONCLUSION: Compared to the alternatives we assessed, CAC testing is both effective and cost saving as a risk-stratification tool, particularly if there are adverse effects of long-term statin use. CAC may enable providers to better tailor preventive therapy to patients' risks of CVD.",2015-01-18478,25786208,PLoS One,Eric T Roberts,2015,10 / 3,e0116377,No,25786208,"Eric T Roberts; Aaron Horne; Seth S Martin; Michael J Blaha; Ron Blankstein; Matthew J Budoff; Christopher Sibley; Joseph F Polak; Kevin D Frick; Roger S Blumenthal; Khurram Nasir; Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA), PLoS One , 2015; 10(3):1932-6203; e0116377",QALY,United States of America,Not Stated,Not Stated,Adding coronary artery calcium to traditional risk factors in cardiovascular disease risk classification vs. Treat all coronary heart disease without risk classification,Not Stated,Not Stated,19 Years,"Female, Male",Full,"5 Years, 10 years",3.00,3.00,Not Stated,United States,2011,Not Stated
14446,Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA),"BACKGROUND: The Multi-Ethnic Study of Atherosclerosis (MESA) showed that the addition of coronary artery calcium (CAC) to traditional risk factors improves risk classification, particularly in intermediate risk asymptomatic patients with LDL cholesterol levels <160 mg/dL. However, the cost-effectiveness of incorporating CAC into treatment decision rules has yet to be clearly delineated. OBJECTIVE: To model the cost-effectiveness of CAC for cardiovascular risk stratification in asymptomatic, intermediate risk patients not taking a statin. Treatment based on CAC was compared to (1) treatment of all intermediate-risk patients, and (2) treatment on the basis of United States guidelines. METHODS: We developed a Markov model of first coronary heart disease (CHD) and cardiovascular disease (CVD) events. We modeled statin treatment in intermediate risk patients with CAC>/=1 and CAC>/=100, with different intensities of statins based on the CAC score. We compared these CAC-based treatment strategies to a ""treat all"" strategy and to treatment according to the Adult Treatment Panel III (ATP III) guidelines. Clinical and economic outcomes were modeled over both five- and ten-year time horizons. Outcomes consisted of CHD and CVD events and Quality-Adjusted Life Years (QALYs). Sensitivity analyses considered the effect of higher event rates, different CAC and statin costs, indirect costs, and re-scanning patients with incidentalomas. RESULTS: We project that it is both cost-saving and more effective to scan intermediate-risk patients for CAC and to treat those with CAC>/=1, compared to treatment based on established risk-assessment guidelines. Treating patients with CAC>/=100 is also preferred to existing guidelines when we account for statin side effects and the disutility of statin use. CONCLUSION: Compared to the alternatives we assessed, CAC testing is both effective and cost saving as a risk-stratification tool, particularly if there are adverse effects of long-term statin use. CAC may enable providers to better tailor preventive therapy to patients' risks of CVD.",2015-01-18478,25786208,PLoS One,Eric T Roberts,2015,10 / 3,e0116377,No,25786208,"Eric T Roberts; Aaron Horne; Seth S Martin; Michael J Blaha; Ron Blankstein; Matthew J Budoff; Christopher Sibley; Joseph F Polak; Kevin D Frick; Roger S Blumenthal; Khurram Nasir; Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA), PLoS One , 2015; 10(3):1932-6203; e0116377",QALY,United States of America,Not Stated,Not Stated,Adding coronary artery calcium to traditional risk factors in coronary heart disease risk classification vs. Standard/Usual Care- Using Adult Treatment Panel III guidelines in coronary heart disease risk classification,Not Stated,Not Stated,19 Years,"Female, Male",Full,"5 Years, 10 years",3.00,3.00,Not Stated,United States,2011,Not Stated
14447,Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA),"BACKGROUND: The Multi-Ethnic Study of Atherosclerosis (MESA) showed that the addition of coronary artery calcium (CAC) to traditional risk factors improves risk classification, particularly in intermediate risk asymptomatic patients with LDL cholesterol levels <160 mg/dL. However, the cost-effectiveness of incorporating CAC into treatment decision rules has yet to be clearly delineated. OBJECTIVE: To model the cost-effectiveness of CAC for cardiovascular risk stratification in asymptomatic, intermediate risk patients not taking a statin. Treatment based on CAC was compared to (1) treatment of all intermediate-risk patients, and (2) treatment on the basis of United States guidelines. METHODS: We developed a Markov model of first coronary heart disease (CHD) and cardiovascular disease (CVD) events. We modeled statin treatment in intermediate risk patients with CAC>/=1 and CAC>/=100, with different intensities of statins based on the CAC score. We compared these CAC-based treatment strategies to a ""treat all"" strategy and to treatment according to the Adult Treatment Panel III (ATP III) guidelines. Clinical and economic outcomes were modeled over both five- and ten-year time horizons. Outcomes consisted of CHD and CVD events and Quality-Adjusted Life Years (QALYs). Sensitivity analyses considered the effect of higher event rates, different CAC and statin costs, indirect costs, and re-scanning patients with incidentalomas. RESULTS: We project that it is both cost-saving and more effective to scan intermediate-risk patients for CAC and to treat those with CAC>/=1, compared to treatment based on established risk-assessment guidelines. Treating patients with CAC>/=100 is also preferred to existing guidelines when we account for statin side effects and the disutility of statin use. CONCLUSION: Compared to the alternatives we assessed, CAC testing is both effective and cost saving as a risk-stratification tool, particularly if there are adverse effects of long-term statin use. CAC may enable providers to better tailor preventive therapy to patients' risks of CVD.",2015-01-18478,25786208,PLoS One,Eric T Roberts,2015,10 / 3,e0116377,No,25786208,"Eric T Roberts; Aaron Horne; Seth S Martin; Michael J Blaha; Ron Blankstein; Matthew J Budoff; Christopher Sibley; Joseph F Polak; Kevin D Frick; Roger S Blumenthal; Khurram Nasir; Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA), PLoS One , 2015; 10(3):1932-6203; e0116377",QALY,United States of America,Not Stated,Not Stated,Adding coronary artery calcium to traditional risk factors in cardiovascular disease risk classification vs. Standard/Usual Care- Using Adult Treatment Panel III guidelines in cardiovascular disease disease risk classification,Not Stated,Not Stated,19 Years,"Female, Male",Full,"5 Years, 10 years",3.00,3.00,Not Stated,United States,2011,Not Stated
14448,Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA),"BACKGROUND: The Multi-Ethnic Study of Atherosclerosis (MESA) showed that the addition of coronary artery calcium (CAC) to traditional risk factors improves risk classification, particularly in intermediate risk asymptomatic patients with LDL cholesterol levels <160 mg/dL. However, the cost-effectiveness of incorporating CAC into treatment decision rules has yet to be clearly delineated. OBJECTIVE: To model the cost-effectiveness of CAC for cardiovascular risk stratification in asymptomatic, intermediate risk patients not taking a statin. Treatment based on CAC was compared to (1) treatment of all intermediate-risk patients, and (2) treatment on the basis of United States guidelines. METHODS: We developed a Markov model of first coronary heart disease (CHD) and cardiovascular disease (CVD) events. We modeled statin treatment in intermediate risk patients with CAC>/=1 and CAC>/=100, with different intensities of statins based on the CAC score. We compared these CAC-based treatment strategies to a ""treat all"" strategy and to treatment according to the Adult Treatment Panel III (ATP III) guidelines. Clinical and economic outcomes were modeled over both five- and ten-year time horizons. Outcomes consisted of CHD and CVD events and Quality-Adjusted Life Years (QALYs). Sensitivity analyses considered the effect of higher event rates, different CAC and statin costs, indirect costs, and re-scanning patients with incidentalomas. RESULTS: We project that it is both cost-saving and more effective to scan intermediate-risk patients for CAC and to treat those with CAC>/=1, compared to treatment based on established risk-assessment guidelines. Treating patients with CAC>/=100 is also preferred to existing guidelines when we account for statin side effects and the disutility of statin use. CONCLUSION: Compared to the alternatives we assessed, CAC testing is both effective and cost saving as a risk-stratification tool, particularly if there are adverse effects of long-term statin use. CAC may enable providers to better tailor preventive therapy to patients' risks of CVD.",2015-01-18478,25786208,PLoS One,Eric T Roberts,2015,10 / 3,e0116377,No,25786208,"Eric T Roberts; Aaron Horne; Seth S Martin; Michael J Blaha; Ron Blankstein; Matthew J Budoff; Christopher Sibley; Joseph F Polak; Kevin D Frick; Roger S Blumenthal; Khurram Nasir; Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA), PLoS One , 2015; 10(3):1932-6203; e0116377",QALY,United States of America,Not Stated,Not Stated,Adding coronary artery calcium to traditional risk factors in cardiovascular disease risk classification vs. Treat all cardiovascular disease without risk classification,Not Stated,Not Stated,19 Years,"Female, Male",Full,"5 Years, 10 years",3.00,3.00,Not Stated,United States,2011,Not Stated
14449,Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA),"BACKGROUND: The Multi-Ethnic Study of Atherosclerosis (MESA) showed that the addition of coronary artery calcium (CAC) to traditional risk factors improves risk classification, particularly in intermediate risk asymptomatic patients with LDL cholesterol levels <160 mg/dL. However, the cost-effectiveness of incorporating CAC into treatment decision rules has yet to be clearly delineated. OBJECTIVE: To model the cost-effectiveness of CAC for cardiovascular risk stratification in asymptomatic, intermediate risk patients not taking a statin. Treatment based on CAC was compared to (1) treatment of all intermediate-risk patients, and (2) treatment on the basis of United States guidelines. METHODS: We developed a Markov model of first coronary heart disease (CHD) and cardiovascular disease (CVD) events. We modeled statin treatment in intermediate risk patients with CAC>/=1 and CAC>/=100, with different intensities of statins based on the CAC score. We compared these CAC-based treatment strategies to a ""treat all"" strategy and to treatment according to the Adult Treatment Panel III (ATP III) guidelines. Clinical and economic outcomes were modeled over both five- and ten-year time horizons. Outcomes consisted of CHD and CVD events and Quality-Adjusted Life Years (QALYs). Sensitivity analyses considered the effect of higher event rates, different CAC and statin costs, indirect costs, and re-scanning patients with incidentalomas. RESULTS: We project that it is both cost-saving and more effective to scan intermediate-risk patients for CAC and to treat those with CAC>/=1, compared to treatment based on established risk-assessment guidelines. Treating patients with CAC>/=100 is also preferred to existing guidelines when we account for statin side effects and the disutility of statin use. CONCLUSION: Compared to the alternatives we assessed, CAC testing is both effective and cost saving as a risk-stratification tool, particularly if there are adverse effects of long-term statin use. CAC may enable providers to better tailor preventive therapy to patients' risks of CVD.",2015-01-18478,25786208,PLoS One,Eric T Roberts,2015,10 / 3,e0116377,No,25786208,"Eric T Roberts; Aaron Horne; Seth S Martin; Michael J Blaha; Ron Blankstein; Matthew J Budoff; Christopher Sibley; Joseph F Polak; Kevin D Frick; Roger S Blumenthal; Khurram Nasir; Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA), PLoS One , 2015; 10(3):1932-6203; e0116377",QALY,United States of America,Not Stated,Not Stated,Adding coronary artery calcium to traditional risk factors in cardiovascular disease risk classification vs. Treat all cardiovascular disease without risk classification,Not Stated,Not Stated,19 Years,"Female, Male",Full,"5 Years, 10 years",3.00,3.00,Not Stated,United States,2011,Not Stated
14450,Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA),"BACKGROUND: The Multi-Ethnic Study of Atherosclerosis (MESA) showed that the addition of coronary artery calcium (CAC) to traditional risk factors improves risk classification, particularly in intermediate risk asymptomatic patients with LDL cholesterol levels <160 mg/dL. However, the cost-effectiveness of incorporating CAC into treatment decision rules has yet to be clearly delineated. OBJECTIVE: To model the cost-effectiveness of CAC for cardiovascular risk stratification in asymptomatic, intermediate risk patients not taking a statin. Treatment based on CAC was compared to (1) treatment of all intermediate-risk patients, and (2) treatment on the basis of United States guidelines. METHODS: We developed a Markov model of first coronary heart disease (CHD) and cardiovascular disease (CVD) events. We modeled statin treatment in intermediate risk patients with CAC>/=1 and CAC>/=100, with different intensities of statins based on the CAC score. We compared these CAC-based treatment strategies to a ""treat all"" strategy and to treatment according to the Adult Treatment Panel III (ATP III) guidelines. Clinical and economic outcomes were modeled over both five- and ten-year time horizons. Outcomes consisted of CHD and CVD events and Quality-Adjusted Life Years (QALYs). Sensitivity analyses considered the effect of higher event rates, different CAC and statin costs, indirect costs, and re-scanning patients with incidentalomas. RESULTS: We project that it is both cost-saving and more effective to scan intermediate-risk patients for CAC and to treat those with CAC>/=1, compared to treatment based on established risk-assessment guidelines. Treating patients with CAC>/=100 is also preferred to existing guidelines when we account for statin side effects and the disutility of statin use. CONCLUSION: Compared to the alternatives we assessed, CAC testing is both effective and cost saving as a risk-stratification tool, particularly if there are adverse effects of long-term statin use. CAC may enable providers to better tailor preventive therapy to patients' risks of CVD.",2015-01-18478,25786208,PLoS One,Eric T Roberts,2015,10 / 3,e0116377,No,25786208,"Eric T Roberts; Aaron Horne; Seth S Martin; Michael J Blaha; Ron Blankstein; Matthew J Budoff; Christopher Sibley; Joseph F Polak; Kevin D Frick; Roger S Blumenthal; Khurram Nasir; Cost-effectiveness of coronary artery calcium testing for coronary heart and cardiovascular disease risk prediction to guide statin allocation: the Multi-Ethnic Study of Atherosclerosis (MESA), PLoS One , 2015; 10(3):1932-6203; e0116377",QALY,United States of America,Not Stated,Not Stated,Adding coronary artery calcium to traditional risk factors in cardiovascular disease risk classification vs. Using Adult Treatment Panel III guidelines in cardiovascular disease risk classification,Not Stated,Not Stated,19 Years,"Female, Male",Full,"5 Years, 10 years",3.00,3.00,Not Stated,United States,2011,Not Stated
14451,Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection,"OBJECTIVE: Clostridium difficile infection (CDI) places a high burden on the US healthcare system. Recurrent CDI (RCDI) occurs frequently. Recently proposed guidelines from the American College of Gastroenterology (ACG) and the American Gastroenterology Association (AGA) include fecal microbiota transplantation (FMT) as a therapeutic option for RCDI. The purpose of this study was to estimate the cost-effectiveness of FMT compared with vancomycin for the treatment of RCDI in adults, specifically following guidelines proposed by the ACG and AGA. DESIGN: We constructed a decision-analytic computer simulation using inputs from the published literature to compare the standard approach using tapered vancomycin to FMT for RCDI from the third-party payer perspective. Our effectiveness measure was quality-adjusted life years (QALYs). Because simulated patients were followed for 90 days, discounting was not necessary. One-way and probabilistic sensitivity analyses were performed. RESULTS: Base-case analysis showed that FMT was less costly ($1,669 vs $3,788) and more effective (0.242 QALYs vs 0.235 QALYs) than vancomycin for RCDI. One-way sensitivity analyses showed that FMT was the dominant strategy (both less expensive and more effective) if cure rates for FMT and vancomycin were >/=70% and <91%, respectively, and if the cost of FMT was <$3,206. Probabilistic sensitivity analysis, varying all parameters simultaneously, showed that FMT was the dominant strategy over 10, 000 second-order Monte Carlo simulations. CONCLUSIONS: Our results suggest that FMT may be a cost-saving intervention in managing RCDI. Implementation of FMT for RCDI may help decrease the economic burden to the healthcare system.",2015-01-18490,25782899,Infect Control Hosp Epidemiol,Raghu U Varier,2015,36 / 4,438-44,No,25782899,"Raghu U Varier; Eman Biltaji; Kenneth J Smith; Mark S Roberts; M Kyle Jensen; Joanne Lafleur; Richard E Nelson; Cost-effectiveness analysis of fecal microbiota transplantation for recurrent Clostridium difficile infection, Infect Control Hosp Epidemiol, 2015 Apr; 36(4):0899-823X; 438-44",QALY,United States of America,Not Stated,Not Stated,"Fecal microbiota transplantation, administered via colonoscopy vs. Standard/Usual Care- Vancomycin, 250 mg every 6 hours for 2 weeks followed by a 6-week oral vancomycin taper",Not Stated,Not Stated,19 Years,"Female, Male",Full,13 Weeks,Not Stated,Not Stated,-302714.28,United States,2011,-348297.92
14452,Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis,"OBJECTIVE: To estimate the cost-effectiveness of noncardia gastric adenocarcinoma (NCGA) screening strategies based on new biomarker and endoscopic technologies. DESIGN: Using an intestinal-type NCGA microsimulation model, we evaluated the following one-time screening strategies for US men: (1) serum pepsinogen to detect gastric atrophy (with endoscopic follow-up of positive screen results), (2) endoscopic screening to detect dysplasia and asymptomatic cancer (with endoscopic mucosal resection (EMR) treatment for detected lesions) and (3) Helicobacter pylori screening and treatment. Screening performance, treatment effectiveness, cancer and cost data were based on published literature and databases. Subgroups included current, former and never smokers. Outcomes included lifetime cancer risk and incremental cost-effectiveness ratios (ICERs), expressed as cost per quality-adjusted-life-year (QALY) gained. RESULTS: Screening the general population at age 50 years reduced the lifetime intestinal-type NCGA risk (0.24%) by 26.4% with serum pepsinogen screening, 21.2% with endoscopy and EMR and 0.2% with H. pylori screening/treatment. Targeting current smokers reduced the lifetime risk (0.35%) by 30.8%, 25.5%, and 0.1%, respectively. For all subgroups, serum pepsinogen screening was more effective and more cost-effective than all other strategies, although its ICER varied from $76 000/QALY (current smokers) to $105 400/QALY (general population). Results were sensitive to H. pylori prevalence, screen age and serum pepsinogen test sensitivity. Probabilistic sensitivity analysis found that at a $100 000/QALY willingness-to-pay threshold, the probability that serum pepsinogen screening was preferred was 0.97 for current smokers. CONCLUSIONS: Although not warranted for the general population, targeting high-risk smokers for serum pepsinogen screening may be a cost-effective strategy to reduce intestinal-type NCGA mortality.",2015-01-18495,25779597,J Nucl Med,Jennifer M Yeh,2015,/,,No,25779597,"Jennifer M Yeh; Chin Hur; Zachary Ward; Deborah Schrag; Sue J Goldie; Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis, J Nucl Med, 2015 May 18; ():1535-5667",QALY,United States of America,Not Stated,Not Stated,Helicobacter pylori screening for gastric adenocarcinoma vs. None,Not Stated,Not Stated,19 Years,Male,Full,Lifetime,3.00,3.00,Not Stated,United States,2012,Not Stated
14453,Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis,"OBJECTIVE: To estimate the cost-effectiveness of noncardia gastric adenocarcinoma (NCGA) screening strategies based on new biomarker and endoscopic technologies. DESIGN: Using an intestinal-type NCGA microsimulation model, we evaluated the following one-time screening strategies for US men: (1) serum pepsinogen to detect gastric atrophy (with endoscopic follow-up of positive screen results), (2) endoscopic screening to detect dysplasia and asymptomatic cancer (with endoscopic mucosal resection (EMR) treatment for detected lesions) and (3) Helicobacter pylori screening and treatment. Screening performance, treatment effectiveness, cancer and cost data were based on published literature and databases. Subgroups included current, former and never smokers. Outcomes included lifetime cancer risk and incremental cost-effectiveness ratios (ICERs), expressed as cost per quality-adjusted-life-year (QALY) gained. RESULTS: Screening the general population at age 50 years reduced the lifetime intestinal-type NCGA risk (0.24%) by 26.4% with serum pepsinogen screening, 21.2% with endoscopy and EMR and 0.2% with H. pylori screening/treatment. Targeting current smokers reduced the lifetime risk (0.35%) by 30.8%, 25.5%, and 0.1%, respectively. For all subgroups, serum pepsinogen screening was more effective and more cost-effective than all other strategies, although its ICER varied from $76 000/QALY (current smokers) to $105 400/QALY (general population). Results were sensitive to H. pylori prevalence, screen age and serum pepsinogen test sensitivity. Probabilistic sensitivity analysis found that at a $100 000/QALY willingness-to-pay threshold, the probability that serum pepsinogen screening was preferred was 0.97 for current smokers. CONCLUSIONS: Although not warranted for the general population, targeting high-risk smokers for serum pepsinogen screening may be a cost-effective strategy to reduce intestinal-type NCGA mortality.",2015-01-18495,25779597,J Nucl Med,Jennifer M Yeh,2015,/,,No,25779597,"Jennifer M Yeh; Chin Hur; Zachary Ward; Deborah Schrag; Sue J Goldie; Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis, J Nucl Med, 2015 May 18; ():1535-5667",QALY,United States of America,Not Stated,Not Stated,Serum pepsinogen screening for gastric adenocarcinoma vs. None,Not Stated,20 Years,20 Years,Male,Full,Lifetime,3.00,3.00,105400,United States,2012,118812.68
14454,Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis,"OBJECTIVE: To estimate the cost-effectiveness of noncardia gastric adenocarcinoma (NCGA) screening strategies based on new biomarker and endoscopic technologies. DESIGN: Using an intestinal-type NCGA microsimulation model, we evaluated the following one-time screening strategies for US men: (1) serum pepsinogen to detect gastric atrophy (with endoscopic follow-up of positive screen results), (2) endoscopic screening to detect dysplasia and asymptomatic cancer (with endoscopic mucosal resection (EMR) treatment for detected lesions) and (3) Helicobacter pylori screening and treatment. Screening performance, treatment effectiveness, cancer and cost data were based on published literature and databases. Subgroups included current, former and never smokers. Outcomes included lifetime cancer risk and incremental cost-effectiveness ratios (ICERs), expressed as cost per quality-adjusted-life-year (QALY) gained. RESULTS: Screening the general population at age 50 years reduced the lifetime intestinal-type NCGA risk (0.24%) by 26.4% with serum pepsinogen screening, 21.2% with endoscopy and EMR and 0.2% with H. pylori screening/treatment. Targeting current smokers reduced the lifetime risk (0.35%) by 30.8%, 25.5%, and 0.1%, respectively. For all subgroups, serum pepsinogen screening was more effective and more cost-effective than all other strategies, although its ICER varied from $76 000/QALY (current smokers) to $105 400/QALY (general population). Results were sensitive to H. pylori prevalence, screen age and serum pepsinogen test sensitivity. Probabilistic sensitivity analysis found that at a $100 000/QALY willingness-to-pay threshold, the probability that serum pepsinogen screening was preferred was 0.97 for current smokers. CONCLUSIONS: Although not warranted for the general population, targeting high-risk smokers for serum pepsinogen screening may be a cost-effective strategy to reduce intestinal-type NCGA mortality.",2015-01-18495,25779597,J Nucl Med,Jennifer M Yeh,2015,/,,No,25779597,"Jennifer M Yeh; Chin Hur; Zachary Ward; Deborah Schrag; Sue J Goldie; Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis, J Nucl Med, 2015 May 18; ():1535-5667",QALY,United States of America,Not Stated,Not Stated,Endoscopic screening for gastric adenocarcinoma vs. Serum pepsinogen screening for gastric adenocarcinoma,Not Stated,Not Stated,19 Years,Male,Full,Lifetime,3.00,3.00,-488500,United States,2012,-550664.1
14455,"The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus","BACKGROUND: New hepatitis C virus (HCV) treatments deliver higher cure rates with fewer contraindications, increasing demand for treatment and healthcare costs. The cost-effectiveness of new treatments is unknown. METHODS: We conducted a microsimulation of guideline testing followed by alternative treatment regimens for HCV among the US population aged 20 and older to estimate cases identified, treated, sustained viral response, deaths, medical costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) of different treatment options expressed as discounted lifetime costs and benefits from the healthcare perspective. RESULTS: Compared to treatment with pegylated interferon and ribavirin (PR), and a protease inhibitor for HCV genotype (G) 1 and PR alone for G2/3, treatment with PR and Sofosbuvir (PRS) for G1/4 and treatment with Sofosbuvir and ribavirin (SR) for G2/3 increased QALYs by 555 226, reduced deaths by 80 682, and increased costs by $26.2 billion at an ICER of $47 304 per QALY gained. As compared to PRS/SR, treating with an all oral regimen of Sofosbuvir and Simeprevir (SS) for G1/4 and SR for G2/3, increased QALYs by 1 110 451 and reduced deaths by an additional 164 540 at an incremental cost of $80.1 billion and an ICER of $72 169. In sensitivity analysis, where treatment with SS effectiveness was set to the list price of Viekira Pak and then Harvoni, treatment cost $24 921 and $25 405 per QALY gained as compared to PRS/SR. CONCLUSIONS: New treatments are cost-effectiveness per person treated, but pent-up demand for treatment may create challenges for financing.",2015-01-18497,25778747,Clin Infect Dis,David B Rein,2015,61 / 2,157-68,No,25778747,"David B Rein; John S Wittenborn; Bryce D Smith; Danielle K Liffmann; John W Ward; The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus, Clin Infect Dis, 2015 Jul 15; 61(2):1537-6591; 157-68",QALY,United States of America,Not Stated,Not Stated,"Pegylated interferon and ribavirin for 48 weeks for genotypes 1 and 4, and for 24 weeks for genotypes 2 and 3 vs. None",Not Stated,Not Stated,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,59792,United States,2013,66427.83
14456,"The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus","BACKGROUND: New hepatitis C virus (HCV) treatments deliver higher cure rates with fewer contraindications, increasing demand for treatment and healthcare costs. The cost-effectiveness of new treatments is unknown. METHODS: We conducted a microsimulation of guideline testing followed by alternative treatment regimens for HCV among the US population aged 20 and older to estimate cases identified, treated, sustained viral response, deaths, medical costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) of different treatment options expressed as discounted lifetime costs and benefits from the healthcare perspective. RESULTS: Compared to treatment with pegylated interferon and ribavirin (PR), and a protease inhibitor for HCV genotype (G) 1 and PR alone for G2/3, treatment with PR and Sofosbuvir (PRS) for G1/4 and treatment with Sofosbuvir and ribavirin (SR) for G2/3 increased QALYs by 555 226, reduced deaths by 80 682, and increased costs by $26.2 billion at an ICER of $47 304 per QALY gained. As compared to PRS/SR, treating with an all oral regimen of Sofosbuvir and Simeprevir (SS) for G1/4 and SR for G2/3, increased QALYs by 1 110 451 and reduced deaths by an additional 164 540 at an incremental cost of $80.1 billion and an ICER of $72 169. In sensitivity analysis, where treatment with SS effectiveness was set to the list price of Viekira Pak and then Harvoni, treatment cost $24 921 and $25 405 per QALY gained as compared to PRS/SR. CONCLUSIONS: New treatments are cost-effectiveness per person treated, but pent-up demand for treatment may create challenges for financing.",2015-01-18497,25778747,Clin Infect Dis,David B Rein,2015,61 / 2,157-68,No,25778747,"David B Rein; John S Wittenborn; Bryce D Smith; Danielle K Liffmann; John W Ward; The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus, Clin Infect Dis, 2015 Jul 15; 61(2):1537-6591; 157-68",QALY,United States of America,Not Stated,Not Stated,Pegylated interferon and ribavirin (PR) for 24 weeks plus an additional protease inhibitor for 12 weeks for genotypes 1 and 4; or PR for 24 weeks for genotypes 2 and 3 vs. None,Not Stated,Not Stated,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,43530,United States,2013,48361.04
14457,"The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus","BACKGROUND: New hepatitis C virus (HCV) treatments deliver higher cure rates with fewer contraindications, increasing demand for treatment and healthcare costs. The cost-effectiveness of new treatments is unknown. METHODS: We conducted a microsimulation of guideline testing followed by alternative treatment regimens for HCV among the US population aged 20 and older to estimate cases identified, treated, sustained viral response, deaths, medical costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) of different treatment options expressed as discounted lifetime costs and benefits from the healthcare perspective. RESULTS: Compared to treatment with pegylated interferon and ribavirin (PR), and a protease inhibitor for HCV genotype (G) 1 and PR alone for G2/3, treatment with PR and Sofosbuvir (PRS) for G1/4 and treatment with Sofosbuvir and ribavirin (SR) for G2/3 increased QALYs by 555 226, reduced deaths by 80 682, and increased costs by $26.2 billion at an ICER of $47 304 per QALY gained. As compared to PRS/SR, treating with an all oral regimen of Sofosbuvir and Simeprevir (SS) for G1/4 and SR for G2/3, increased QALYs by 1 110 451 and reduced deaths by an additional 164 540 at an incremental cost of $80.1 billion and an ICER of $72 169. In sensitivity analysis, where treatment with SS effectiveness was set to the list price of Viekira Pak and then Harvoni, treatment cost $24 921 and $25 405 per QALY gained as compared to PRS/SR. CONCLUSIONS: New treatments are cost-effectiveness per person treated, but pent-up demand for treatment may create challenges for financing.",2015-01-18497,25778747,Clin Infect Dis,David B Rein,2015,61 / 2,157-68,No,25778747,"David B Rein; John S Wittenborn; Bryce D Smith; Danielle K Liffmann; John W Ward; The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus, Clin Infect Dis, 2015 Jul 15; 61(2):1537-6591; 157-68",QALY,United States of America,Not Stated,Not Stated,"Pegylated interferon and ribavirin plus sofosbuvir for 12 weeks for genotypes 1 and 4, sofosbuvir plus ribavirin (SR) for 12 weeks for genotype 2, and SR for 24 weeks for genotype 3 vs. Pegylated interferon and ribavirin (PR) for 24 weeks plus an additional protease inhibitor for 12 weeks for genotypes 1 and 4; or PR for 24 weeks for genotypes 2 and 3",Not Stated,Not Stated,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,47237,United States,2013,52479.45
14458,"The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus","BACKGROUND: New hepatitis C virus (HCV) treatments deliver higher cure rates with fewer contraindications, increasing demand for treatment and healthcare costs. The cost-effectiveness of new treatments is unknown. METHODS: We conducted a microsimulation of guideline testing followed by alternative treatment regimens for HCV among the US population aged 20 and older to estimate cases identified, treated, sustained viral response, deaths, medical costs, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) of different treatment options expressed as discounted lifetime costs and benefits from the healthcare perspective. RESULTS: Compared to treatment with pegylated interferon and ribavirin (PR), and a protease inhibitor for HCV genotype (G) 1 and PR alone for G2/3, treatment with PR and Sofosbuvir (PRS) for G1/4 and treatment with Sofosbuvir and ribavirin (SR) for G2/3 increased QALYs by 555 226, reduced deaths by 80 682, and increased costs by $26.2 billion at an ICER of $47 304 per QALY gained. As compared to PRS/SR, treating with an all oral regimen of Sofosbuvir and Simeprevir (SS) for G1/4 and SR for G2/3, increased QALYs by 1 110 451 and reduced deaths by an additional 164 540 at an incremental cost of $80.1 billion and an ICER of $72 169. In sensitivity analysis, where treatment with SS effectiveness was set to the list price of Viekira Pak and then Harvoni, treatment cost $24 921 and $25 405 per QALY gained as compared to PRS/SR. CONCLUSIONS: New treatments are cost-effectiveness per person treated, but pent-up demand for treatment may create challenges for financing.",2015-01-18497,25778747,Clin Infect Dis,David B Rein,2015,61 / 2,157-68,No,25778747,"David B Rein; John S Wittenborn; Bryce D Smith; Danielle K Liffmann; John W Ward; The cost-effectiveness, health benefits, and financial costs of new antiviral treatments for hepatitis C virus, Clin Infect Dis, 2015 Jul 15; 61(2):1537-6591; 157-68",QALY,United States of America,Not Stated,Not Stated,"Simeprevir and sofosbuvir for 12 weeks for genotypes 1 and 4, sofosbuvir plus ribavirin for 12 weeks for genotype 2, and sofosbuvir plus ribavirin for 24 weeks for genotype 3 vs. Pegylated interferon and ribavirin plus sofosbuvir for 12 weeks for genotypes 1 and 4, sofosbuvir plus ribavirin (SR) for 12 weeks for genotype 2, and SR for 24 weeks for genotype 3",Not Stated,Not Stated,20 Years,"Female, Male",Full,Lifetime,3.00,3.00,72169,United States,2013,80178.45
14459,Cost-effectiveness of novel regimens for the treatment of hepatitis C virus,"BACKGROUND: New regimens for hepatitis C virus (HCV) have shorter treatment durations and increased rates of sustained virologic response compared with existing therapies but are extremely expensive. OBJECTIVE: To evaluate the cost-effectiveness of these treatments under different assumptions about their price and efficacy. DESIGN: Discrete-event simulation. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive patients infected with chronic HCV genotype 1, 2, or 3. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Usual care (boceprevir-ribavirin-pegylated interferon [PEG]) was compared with sofosbuvir-ribavirin-PEG and 3 PEG-free regimens: sofosbuvir-simeprevir, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir. For genotypes 2 and 3, usual care (ribavirin-PEG) was compared with sofosbuvir-ribavirin, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir-ribavirin (genotype 3 only). OUTCOME MEASURES: Discounted costs (in 2014 U.S. dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: Assuming sofosbuvir, simeprevir, daclatasvir, and ledipasvir cost $7000, $5500, $5500, and $875 per week, respectively, sofosbuvir-ledipasvir was cost-effective for genotype 1 and cost $12 825 more per QALY than usual care. For genotype 2, sofosbuvir-ribavirin and sofosbuvir-daclatasvir cost $110 000 and $691 000 per QALY, respectively. For genotype 3, sofosbuvir-ledipasvir-ribavirin cost $73 000 per QALY, sofosbuvir-ribavirin was more costly and less effective than usual care, and sofosbuvir-daclatasvir cost more than $396 000 per QALY at assumed prices. RESULTS OF SENSITIVITY ANALYSIS: Sofosbuvir-ledipasvir was the optimal strategy in most simulations for genotype 1 and would be cost-saving if sofosbuvir cost less than $5500. For genotype 2, sofosbuvir-ribavirin-PEG would be cost-saving if sofosbuvir cost less than $2250 per week. For genotype 3, sofosbuvir-ledipasvir-ribavirin would be cost-saving if sofosbuvir cost less than $1500 per week. LIMITATION: Data are lacking on real-world effectiveness of new treatments and some prices. CONCLUSION: From a societal perspective, novel treatments for HCV are cost-effective compared with usual care for genotype 1 and probably genotype 3 but not for genotype 2. PRIMARY FUNDING SOURCE: CVS Health.",2015-01-18502,25775313,Ann Intern Med,Mehdi Najafzadeh,2015,162 / 6,407-19,No,25775313,"Mehdi Najafzadeh; Karin Andersson; William H Shrank; Alexis A Krumme; Olga S Matlin; Troyen Brennan; Jerry Avorn; Niteesh K Choudhry; Cost-effectiveness of novel regimens for the treatment of hepatitis C virus, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 407-19",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir+ribavirin+PEG (PEG-free regimen) vs. Standard/Usual Care- Boceprevir+ribavirin+pegylated interferon [PEG],"Treatment-naive, infected with chronic hepatitis C virus genotype 1",Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,21528,United States,2014,23535.43
14460,Cost-effectiveness of novel regimens for the treatment of hepatitis C virus,"BACKGROUND: New regimens for hepatitis C virus (HCV) have shorter treatment durations and increased rates of sustained virologic response compared with existing therapies but are extremely expensive. OBJECTIVE: To evaluate the cost-effectiveness of these treatments under different assumptions about their price and efficacy. DESIGN: Discrete-event simulation. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive patients infected with chronic HCV genotype 1, 2, or 3. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Usual care (boceprevir-ribavirin-pegylated interferon [PEG]) was compared with sofosbuvir-ribavirin-PEG and 3 PEG-free regimens: sofosbuvir-simeprevir, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir. For genotypes 2 and 3, usual care (ribavirin-PEG) was compared with sofosbuvir-ribavirin, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir-ribavirin (genotype 3 only). OUTCOME MEASURES: Discounted costs (in 2014 U.S. dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: Assuming sofosbuvir, simeprevir, daclatasvir, and ledipasvir cost $7000, $5500, $5500, and $875 per week, respectively, sofosbuvir-ledipasvir was cost-effective for genotype 1 and cost $12 825 more per QALY than usual care. For genotype 2, sofosbuvir-ribavirin and sofosbuvir-daclatasvir cost $110 000 and $691 000 per QALY, respectively. For genotype 3, sofosbuvir-ledipasvir-ribavirin cost $73 000 per QALY, sofosbuvir-ribavirin was more costly and less effective than usual care, and sofosbuvir-daclatasvir cost more than $396 000 per QALY at assumed prices. RESULTS OF SENSITIVITY ANALYSIS: Sofosbuvir-ledipasvir was the optimal strategy in most simulations for genotype 1 and would be cost-saving if sofosbuvir cost less than $5500. For genotype 2, sofosbuvir-ribavirin-PEG would be cost-saving if sofosbuvir cost less than $2250 per week. For genotype 3, sofosbuvir-ledipasvir-ribavirin would be cost-saving if sofosbuvir cost less than $1500 per week. LIMITATION: Data are lacking on real-world effectiveness of new treatments and some prices. CONCLUSION: From a societal perspective, novel treatments for HCV are cost-effective compared with usual care for genotype 1 and probably genotype 3 but not for genotype 2. PRIMARY FUNDING SOURCE: CVS Health.",2015-01-18502,25775313,Ann Intern Med,Mehdi Najafzadeh,2015,162 / 6,407-19,No,25775313,"Mehdi Najafzadeh; Karin Andersson; William H Shrank; Alexis A Krumme; Olga S Matlin; Troyen Brennan; Jerry Avorn; Niteesh K Choudhry; Cost-effectiveness of novel regimens for the treatment of hepatitis C virus, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 407-19",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir+daclatasvir (PEG-free regimen) vs. Standard/Usual Care- Boceprevir+ribavirin+pegylated interferon [PEG],"Treatment-naive, infected with chronic hepatitis C virus genotype 1",Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,63355,United States,2014,69262.68
14461,Cost-effectiveness of novel regimens for the treatment of hepatitis C virus,"BACKGROUND: New regimens for hepatitis C virus (HCV) have shorter treatment durations and increased rates of sustained virologic response compared with existing therapies but are extremely expensive. OBJECTIVE: To evaluate the cost-effectiveness of these treatments under different assumptions about their price and efficacy. DESIGN: Discrete-event simulation. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive patients infected with chronic HCV genotype 1, 2, or 3. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Usual care (boceprevir-ribavirin-pegylated interferon [PEG]) was compared with sofosbuvir-ribavirin-PEG and 3 PEG-free regimens: sofosbuvir-simeprevir, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir. For genotypes 2 and 3, usual care (ribavirin-PEG) was compared with sofosbuvir-ribavirin, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir-ribavirin (genotype 3 only). OUTCOME MEASURES: Discounted costs (in 2014 U.S. dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: Assuming sofosbuvir, simeprevir, daclatasvir, and ledipasvir cost $7000, $5500, $5500, and $875 per week, respectively, sofosbuvir-ledipasvir was cost-effective for genotype 1 and cost $12 825 more per QALY than usual care. For genotype 2, sofosbuvir-ribavirin and sofosbuvir-daclatasvir cost $110 000 and $691 000 per QALY, respectively. For genotype 3, sofosbuvir-ledipasvir-ribavirin cost $73 000 per QALY, sofosbuvir-ribavirin was more costly and less effective than usual care, and sofosbuvir-daclatasvir cost more than $396 000 per QALY at assumed prices. RESULTS OF SENSITIVITY ANALYSIS: Sofosbuvir-ledipasvir was the optimal strategy in most simulations for genotype 1 and would be cost-saving if sofosbuvir cost less than $5500. For genotype 2, sofosbuvir-ribavirin-PEG would be cost-saving if sofosbuvir cost less than $2250 per week. For genotype 3, sofosbuvir-ledipasvir-ribavirin would be cost-saving if sofosbuvir cost less than $1500 per week. LIMITATION: Data are lacking on real-world effectiveness of new treatments and some prices. CONCLUSION: From a societal perspective, novel treatments for HCV are cost-effective compared with usual care for genotype 1 and probably genotype 3 but not for genotype 2. PRIMARY FUNDING SOURCE: CVS Health.",2015-01-18502,25775313,Ann Intern Med,Mehdi Najafzadeh,2015,162 / 6,407-19,No,25775313,"Mehdi Najafzadeh; Karin Andersson; William H Shrank; Alexis A Krumme; Olga S Matlin; Troyen Brennan; Jerry Avorn; Niteesh K Choudhry; Cost-effectiveness of novel regimens for the treatment of hepatitis C virus, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 407-19",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir+ledipasvir (PEG-free regimen) vs. Standard/Usual Care- Boceprevir+ribavirin+pegylated interferon [PEG],"Treatment-naive, infected with chronic hepatitis C virus genotype 1",Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,12825,United States,2014,14020.9
14462,Cost-effectiveness of novel regimens for the treatment of hepatitis C virus,"BACKGROUND: New regimens for hepatitis C virus (HCV) have shorter treatment durations and increased rates of sustained virologic response compared with existing therapies but are extremely expensive. OBJECTIVE: To evaluate the cost-effectiveness of these treatments under different assumptions about their price and efficacy. DESIGN: Discrete-event simulation. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive patients infected with chronic HCV genotype 1, 2, or 3. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Usual care (boceprevir-ribavirin-pegylated interferon [PEG]) was compared with sofosbuvir-ribavirin-PEG and 3 PEG-free regimens: sofosbuvir-simeprevir, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir. For genotypes 2 and 3, usual care (ribavirin-PEG) was compared with sofosbuvir-ribavirin, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir-ribavirin (genotype 3 only). OUTCOME MEASURES: Discounted costs (in 2014 U.S. dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: Assuming sofosbuvir, simeprevir, daclatasvir, and ledipasvir cost $7000, $5500, $5500, and $875 per week, respectively, sofosbuvir-ledipasvir was cost-effective for genotype 1 and cost $12 825 more per QALY than usual care. For genotype 2, sofosbuvir-ribavirin and sofosbuvir-daclatasvir cost $110 000 and $691 000 per QALY, respectively. For genotype 3, sofosbuvir-ledipasvir-ribavirin cost $73 000 per QALY, sofosbuvir-ribavirin was more costly and less effective than usual care, and sofosbuvir-daclatasvir cost more than $396 000 per QALY at assumed prices. RESULTS OF SENSITIVITY ANALYSIS: Sofosbuvir-ledipasvir was the optimal strategy in most simulations for genotype 1 and would be cost-saving if sofosbuvir cost less than $5500. For genotype 2, sofosbuvir-ribavirin-PEG would be cost-saving if sofosbuvir cost less than $2250 per week. For genotype 3, sofosbuvir-ledipasvir-ribavirin would be cost-saving if sofosbuvir cost less than $1500 per week. LIMITATION: Data are lacking on real-world effectiveness of new treatments and some prices. CONCLUSION: From a societal perspective, novel treatments for HCV are cost-effective compared with usual care for genotype 1 and probably genotype 3 but not for genotype 2. PRIMARY FUNDING SOURCE: CVS Health.",2015-01-18502,25775313,Ann Intern Med,Mehdi Najafzadeh,2015,162 / 6,407-19,No,25775313,"Mehdi Najafzadeh; Karin Andersson; William H Shrank; Alexis A Krumme; Olga S Matlin; Troyen Brennan; Jerry Avorn; Niteesh K Choudhry; Cost-effectiveness of novel regimens for the treatment of hepatitis C virus, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 407-19",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir+simeprevir (PEG-free regimen) vs. Standard/Usual Care- Boceprevir+ribavirin+pegylated interferon [PEG],"Treatment-naive, infected with chronic hepatitis C virus genotype 1",Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,71445,United States,2014,78107.06
14463,Cost-effectiveness of novel regimens for the treatment of hepatitis C virus,"BACKGROUND: New regimens for hepatitis C virus (HCV) have shorter treatment durations and increased rates of sustained virologic response compared with existing therapies but are extremely expensive. OBJECTIVE: To evaluate the cost-effectiveness of these treatments under different assumptions about their price and efficacy. DESIGN: Discrete-event simulation. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive patients infected with chronic HCV genotype 1, 2, or 3. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Usual care (boceprevir-ribavirin-pegylated interferon [PEG]) was compared with sofosbuvir-ribavirin-PEG and 3 PEG-free regimens: sofosbuvir-simeprevir, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir. For genotypes 2 and 3, usual care (ribavirin-PEG) was compared with sofosbuvir-ribavirin, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir-ribavirin (genotype 3 only). OUTCOME MEASURES: Discounted costs (in 2014 U.S. dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: Assuming sofosbuvir, simeprevir, daclatasvir, and ledipasvir cost $7000, $5500, $5500, and $875 per week, respectively, sofosbuvir-ledipasvir was cost-effective for genotype 1 and cost $12 825 more per QALY than usual care. For genotype 2, sofosbuvir-ribavirin and sofosbuvir-daclatasvir cost $110 000 and $691 000 per QALY, respectively. For genotype 3, sofosbuvir-ledipasvir-ribavirin cost $73 000 per QALY, sofosbuvir-ribavirin was more costly and less effective than usual care, and sofosbuvir-daclatasvir cost more than $396 000 per QALY at assumed prices. RESULTS OF SENSITIVITY ANALYSIS: Sofosbuvir-ledipasvir was the optimal strategy in most simulations for genotype 1 and would be cost-saving if sofosbuvir cost less than $5500. For genotype 2, sofosbuvir-ribavirin-PEG would be cost-saving if sofosbuvir cost less than $2250 per week. For genotype 3, sofosbuvir-ledipasvir-ribavirin would be cost-saving if sofosbuvir cost less than $1500 per week. LIMITATION: Data are lacking on real-world effectiveness of new treatments and some prices. CONCLUSION: From a societal perspective, novel treatments for HCV are cost-effective compared with usual care for genotype 1 and probably genotype 3 but not for genotype 2. PRIMARY FUNDING SOURCE: CVS Health.",2015-01-18502,25775313,Ann Intern Med,Mehdi Najafzadeh,2015,162 / 6,407-19,No,25775313,"Mehdi Najafzadeh; Karin Andersson; William H Shrank; Alexis A Krumme; Olga S Matlin; Troyen Brennan; Jerry Avorn; Niteesh K Choudhry; Cost-effectiveness of novel regimens for the treatment of hepatitis C virus, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 407-19",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir+ribavirin (PEG-free regimen) vs. Standard/Usual Care- Ribavirin+pegylated interferon [PEG],"Treatment-naive, infected with chronic hepatitis C virus genotype 2",Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,110168,United States,2014,120440.87
14464,Cost-effectiveness of novel regimens for the treatment of hepatitis C virus,"BACKGROUND: New regimens for hepatitis C virus (HCV) have shorter treatment durations and increased rates of sustained virologic response compared with existing therapies but are extremely expensive. OBJECTIVE: To evaluate the cost-effectiveness of these treatments under different assumptions about their price and efficacy. DESIGN: Discrete-event simulation. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive patients infected with chronic HCV genotype 1, 2, or 3. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Usual care (boceprevir-ribavirin-pegylated interferon [PEG]) was compared with sofosbuvir-ribavirin-PEG and 3 PEG-free regimens: sofosbuvir-simeprevir, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir. For genotypes 2 and 3, usual care (ribavirin-PEG) was compared with sofosbuvir-ribavirin, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir-ribavirin (genotype 3 only). OUTCOME MEASURES: Discounted costs (in 2014 U.S. dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: Assuming sofosbuvir, simeprevir, daclatasvir, and ledipasvir cost $7000, $5500, $5500, and $875 per week, respectively, sofosbuvir-ledipasvir was cost-effective for genotype 1 and cost $12 825 more per QALY than usual care. For genotype 2, sofosbuvir-ribavirin and sofosbuvir-daclatasvir cost $110 000 and $691 000 per QALY, respectively. For genotype 3, sofosbuvir-ledipasvir-ribavirin cost $73 000 per QALY, sofosbuvir-ribavirin was more costly and less effective than usual care, and sofosbuvir-daclatasvir cost more than $396 000 per QALY at assumed prices. RESULTS OF SENSITIVITY ANALYSIS: Sofosbuvir-ledipasvir was the optimal strategy in most simulations for genotype 1 and would be cost-saving if sofosbuvir cost less than $5500. For genotype 2, sofosbuvir-ribavirin-PEG would be cost-saving if sofosbuvir cost less than $2250 per week. For genotype 3, sofosbuvir-ledipasvir-ribavirin would be cost-saving if sofosbuvir cost less than $1500 per week. LIMITATION: Data are lacking on real-world effectiveness of new treatments and some prices. CONCLUSION: From a societal perspective, novel treatments for HCV are cost-effective compared with usual care for genotype 1 and probably genotype 3 but not for genotype 2. PRIMARY FUNDING SOURCE: CVS Health.",2015-01-18502,25775313,Ann Intern Med,Mehdi Najafzadeh,2015,162 / 6,407-19,No,25775313,"Mehdi Najafzadeh; Karin Andersson; William H Shrank; Alexis A Krumme; Olga S Matlin; Troyen Brennan; Jerry Avorn; Niteesh K Choudhry; Cost-effectiveness of novel regimens for the treatment of hepatitis C virus, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 407-19",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir+daclatasvir (PEG-free regimen) vs. Standard/Usual Care- Ribavirin+pegylated interferon [PEG],"Treatment-naive, infected with chronic hepatitis C virus genotype 2",Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,691574,United States,2014,756061.43
14465,Cost-effectiveness of novel regimens for the treatment of hepatitis C virus,"BACKGROUND: New regimens for hepatitis C virus (HCV) have shorter treatment durations and increased rates of sustained virologic response compared with existing therapies but are extremely expensive. OBJECTIVE: To evaluate the cost-effectiveness of these treatments under different assumptions about their price and efficacy. DESIGN: Discrete-event simulation. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive patients infected with chronic HCV genotype 1, 2, or 3. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Usual care (boceprevir-ribavirin-pegylated interferon [PEG]) was compared with sofosbuvir-ribavirin-PEG and 3 PEG-free regimens: sofosbuvir-simeprevir, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir. For genotypes 2 and 3, usual care (ribavirin-PEG) was compared with sofosbuvir-ribavirin, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir-ribavirin (genotype 3 only). OUTCOME MEASURES: Discounted costs (in 2014 U.S. dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: Assuming sofosbuvir, simeprevir, daclatasvir, and ledipasvir cost $7000, $5500, $5500, and $875 per week, respectively, sofosbuvir-ledipasvir was cost-effective for genotype 1 and cost $12 825 more per QALY than usual care. For genotype 2, sofosbuvir-ribavirin and sofosbuvir-daclatasvir cost $110 000 and $691 000 per QALY, respectively. For genotype 3, sofosbuvir-ledipasvir-ribavirin cost $73 000 per QALY, sofosbuvir-ribavirin was more costly and less effective than usual care, and sofosbuvir-daclatasvir cost more than $396 000 per QALY at assumed prices. RESULTS OF SENSITIVITY ANALYSIS: Sofosbuvir-ledipasvir was the optimal strategy in most simulations for genotype 1 and would be cost-saving if sofosbuvir cost less than $5500. For genotype 2, sofosbuvir-ribavirin-PEG would be cost-saving if sofosbuvir cost less than $2250 per week. For genotype 3, sofosbuvir-ledipasvir-ribavirin would be cost-saving if sofosbuvir cost less than $1500 per week. LIMITATION: Data are lacking on real-world effectiveness of new treatments and some prices. CONCLUSION: From a societal perspective, novel treatments for HCV are cost-effective compared with usual care for genotype 1 and probably genotype 3 but not for genotype 2. PRIMARY FUNDING SOURCE: CVS Health.",2015-01-18502,25775313,Ann Intern Med,Mehdi Najafzadeh,2015,162 / 6,407-19,No,25775313,"Mehdi Najafzadeh; Karin Andersson; William H Shrank; Alexis A Krumme; Olga S Matlin; Troyen Brennan; Jerry Avorn; Niteesh K Choudhry; Cost-effectiveness of novel regimens for the treatment of hepatitis C virus, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 407-19",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir+ribavirin(PEG-free regimen) vs. Standard/Usual Care- Ribavirin+pegylated interferon [PEG],"Treatment-naive, infected with chronic hepatitis C virus genotype 3",Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,-1150377,United States,2014,-1257646.58
14466,Cost-effectiveness of novel regimens for the treatment of hepatitis C virus,"BACKGROUND: New regimens for hepatitis C virus (HCV) have shorter treatment durations and increased rates of sustained virologic response compared with existing therapies but are extremely expensive. OBJECTIVE: To evaluate the cost-effectiveness of these treatments under different assumptions about their price and efficacy. DESIGN: Discrete-event simulation. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive patients infected with chronic HCV genotype 1, 2, or 3. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Usual care (boceprevir-ribavirin-pegylated interferon [PEG]) was compared with sofosbuvir-ribavirin-PEG and 3 PEG-free regimens: sofosbuvir-simeprevir, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir. For genotypes 2 and 3, usual care (ribavirin-PEG) was compared with sofosbuvir-ribavirin, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir-ribavirin (genotype 3 only). OUTCOME MEASURES: Discounted costs (in 2014 U.S. dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: Assuming sofosbuvir, simeprevir, daclatasvir, and ledipasvir cost $7000, $5500, $5500, and $875 per week, respectively, sofosbuvir-ledipasvir was cost-effective for genotype 1 and cost $12 825 more per QALY than usual care. For genotype 2, sofosbuvir-ribavirin and sofosbuvir-daclatasvir cost $110 000 and $691 000 per QALY, respectively. For genotype 3, sofosbuvir-ledipasvir-ribavirin cost $73 000 per QALY, sofosbuvir-ribavirin was more costly and less effective than usual care, and sofosbuvir-daclatasvir cost more than $396 000 per QALY at assumed prices. RESULTS OF SENSITIVITY ANALYSIS: Sofosbuvir-ledipasvir was the optimal strategy in most simulations for genotype 1 and would be cost-saving if sofosbuvir cost less than $5500. For genotype 2, sofosbuvir-ribavirin-PEG would be cost-saving if sofosbuvir cost less than $2250 per week. For genotype 3, sofosbuvir-ledipasvir-ribavirin would be cost-saving if sofosbuvir cost less than $1500 per week. LIMITATION: Data are lacking on real-world effectiveness of new treatments and some prices. CONCLUSION: From a societal perspective, novel treatments for HCV are cost-effective compared with usual care for genotype 1 and probably genotype 3 but not for genotype 2. PRIMARY FUNDING SOURCE: CVS Health.",2015-01-18502,25775313,Ann Intern Med,Mehdi Najafzadeh,2015,162 / 6,407-19,No,25775313,"Mehdi Najafzadeh; Karin Andersson; William H Shrank; Alexis A Krumme; Olga S Matlin; Troyen Brennan; Jerry Avorn; Niteesh K Choudhry; Cost-effectiveness of novel regimens for the treatment of hepatitis C virus, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 407-19",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir+daclatasvir (PEG-free regimen) vs. Standard/Usual Care- Ribavirin+pegylated interferon [PEG],"Treatment-naive, infected with chronic hepatitis C virus genotype 3",Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,396229,United States,2014,433176.3
14467,Cost-effectiveness of novel regimens for the treatment of hepatitis C virus,"BACKGROUND: New regimens for hepatitis C virus (HCV) have shorter treatment durations and increased rates of sustained virologic response compared with existing therapies but are extremely expensive. OBJECTIVE: To evaluate the cost-effectiveness of these treatments under different assumptions about their price and efficacy. DESIGN: Discrete-event simulation. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive patients infected with chronic HCV genotype 1, 2, or 3. TIME HORIZON: Lifetime. PERSPECTIVE: Societal. INTERVENTION: Usual care (boceprevir-ribavirin-pegylated interferon [PEG]) was compared with sofosbuvir-ribavirin-PEG and 3 PEG-free regimens: sofosbuvir-simeprevir, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir. For genotypes 2 and 3, usual care (ribavirin-PEG) was compared with sofosbuvir-ribavirin, sofosbuvir-daclatasvir, and sofosbuvir-ledipasvir-ribavirin (genotype 3 only). OUTCOME MEASURES: Discounted costs (in 2014 U.S. dollars), quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratios. RESULTS OF BASE-CASE ANALYSIS: Assuming sofosbuvir, simeprevir, daclatasvir, and ledipasvir cost $7000, $5500, $5500, and $875 per week, respectively, sofosbuvir-ledipasvir was cost-effective for genotype 1 and cost $12 825 more per QALY than usual care. For genotype 2, sofosbuvir-ribavirin and sofosbuvir-daclatasvir cost $110 000 and $691 000 per QALY, respectively. For genotype 3, sofosbuvir-ledipasvir-ribavirin cost $73 000 per QALY, sofosbuvir-ribavirin was more costly and less effective than usual care, and sofosbuvir-daclatasvir cost more than $396 000 per QALY at assumed prices. RESULTS OF SENSITIVITY ANALYSIS: Sofosbuvir-ledipasvir was the optimal strategy in most simulations for genotype 1 and would be cost-saving if sofosbuvir cost less than $5500. For genotype 2, sofosbuvir-ribavirin-PEG would be cost-saving if sofosbuvir cost less than $2250 per week. For genotype 3, sofosbuvir-ledipasvir-ribavirin would be cost-saving if sofosbuvir cost less than $1500 per week. LIMITATION: Data are lacking on real-world effectiveness of new treatments and some prices. CONCLUSION: From a societal perspective, novel treatments for HCV are cost-effective compared with usual care for genotype 1 and probably genotype 3 but not for genotype 2. PRIMARY FUNDING SOURCE: CVS Health.",2015-01-18502,25775313,Ann Intern Med,Mehdi Najafzadeh,2015,162 / 6,407-19,No,25775313,"Mehdi Najafzadeh; Karin Andersson; William H Shrank; Alexis A Krumme; Olga S Matlin; Troyen Brennan; Jerry Avorn; Niteesh K Choudhry; Cost-effectiveness of novel regimens for the treatment of hepatitis C virus, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 407-19",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir+ledipasvir+ribavirin (PEG-free regimen) vs. Standard/Usual Care- Ribavirin+pegylated interferon [PEG],"Treatment-naive, infected with chronic hepatitis C virus genotype 3",Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,72236,United States,2014,78971.81
14468,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Combination of sofosbuvir and ledipasvir vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-nave, infected with chronic hepatitis C virus genotype 1, non-cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,31452,United States,2014,34384.82
14469,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Combination of sofosbuvir and ledipasvir vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-nave, infected with chronic hepatitis C virus genotype 1, cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,9703,United States,2014,10607.78
14470,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-nave, infected with chronic hepatitis C virus genotype 2, non-cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,149463,United States,2014,163400.03
14471,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-nave, infected with chronic hepatitis C virus genotype 2, cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,62428,United States,2014,68249.24
14472,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-nave, infected with chronic hepatitis C virus genotype 3, non-cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,284327,United States,2014,310839.73
14473,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-nave, infected with chronic hepatitis C virus genotype 3, cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,95083,United States,2014,103949.24
14474,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-nave, infected with chronic hepatitis C virus genotype 4, non-cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,81802,United States,2014,89429.82
14475,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-nave, infected with chronic hepatitis C virus genotype 4, cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,30986,United States,2014,33875.36
14476,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-nave, infected with chronic hepatitis C virus genotype 1-4, non-cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,61517,United States,2014,67253.3
14477,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-nave, infected with chronic hepatitis C virus genotype 1-4, cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,20673,United States,2014,22600.7
14478,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),Treatment-nave,Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,43034,United States,2014,47046.81
14479,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Combination of sofosbuvir and ledipasvir vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-experienced, infected with chronic hepatitis C virus genotype 1, non-cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,35853,United States,2014,39196.2
14480,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Combination of sofosbuvir and ledipasvir vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-experienced, infected with chronic hepatitis C virus genotype 1, cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,79238,United States,2014,86626.73
14481,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-experienced, infected with chronic hepatitis C virus genotype 2, non-cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,128770,United States,2014,140777.46
14482,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-experienced, infected with chronic hepatitis C virus genotype 2, cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,281317,United States,2014,307549.06
14483,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-experienced, infected with chronic hepatitis C virus genotype 3, non-cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,410548,United States,2014,448830.5
14484,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-experienced, infected with chronic hepatitis C virus genotype 3, cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,382819,United States,2014,418515.85
14485,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-experienced, infected with chronic hepatitis C virus genotype 4, non-cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,80793,United States,2014,88326.73
14486,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-experienced, infected with chronic hepatitis C virus genotype 4, cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,34349,United States,2014,37551.95
14487,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-experienced, infected with chronic hepatitis C virus genotype 1-4, non-cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,69707,United States,2014,76206.99
14488,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),"Treatment-experienced, infected with chronic hepatitis C virus genotype 1-4, cirrhotic",Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,92302,United States,2014,100908.92
14489,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),Treatment-experienced,Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,79457,United States,2014,86866.15
14490,Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States,"BACKGROUND: Sofosbuvir and ledipasvir, which have recently been approved for treatment of chronic hepatitis C virus (HCV) infection, are more efficacious and safer than the old standard of care (oSOC) but are substantially more expensive. Whether and in which patients their improved efficacy justifies their increased cost is unclear. OBJECTIVE: To evaluate the cost-effectiveness and budget impact of sofosbuvir and ledipasvir. DESIGN: Microsimulation model of the natural history of HCV infection. DATA SOURCES: Published literature. TARGET POPULATION: Treatment-naive and treatment-experienced HCV population defined on the basis of HCV genotype, age, and fibrosis distribution in the United States. TIME HORIZON: Lifetime. PERSPECTIVE: Third-party payer. INTERVENTION: Simulation of sofosbuvir-ledipasvir compared with the oSOC (interferon-based therapies). OUTCOME MEASURES: Quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), and 5-year spending on antiviral drugs. RESULTS OF BASE-CASE ANALYSIS: Sofosbuvir-based therapies added 0.56 QALY relative to the oSOC at an ICER of $55 400 per additional QALY. The ICERs ranged from $9700 to $284 300 per QALY depending on the patient's status with respect to treatment history, HCV genotype, and presence of cirrhosis. At a willingness-to-pay threshold of $100 000 per QALY, sofosbuvir-based therapies were cost-effective in 83% of treatment-naive and 81% of treatment-experienced patients. Compared with the oSOC, treating eligible HCV-infected persons in the United States with the new drugs would cost an additional $65 billion in the next 5 years, whereas the resulting cost offsets would be $16 billion. RESULTS OF SENSITIVITY ANALYSIS: Results were sensitive to drug price, drug efficacy, and quality of life after successful treatment. LIMITATION: Data on real-world effectiveness of new antivirals are lacking. CONCLUSION: Treatment of HCV is cost-effective in most patients, but additional resources and value-based patient prioritization are needed to manage patients with HCV. PRIMARY FUNDING SOURCE: National Institutes of Health.",2015-01-18503,25775312,Ann Intern Med,Jagpreet Chhatwal,2015,162 / 6,397-406,No,25775312,"Jagpreet Chhatwal; Fasiha Kanwal; Mark S Roberts; Michael A Dunn; Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States, Ann Intern Med, 2015 Mar 17; 162(6):1539-3704; 397-406",QALY,United States of America,Not Stated,Not Stated,Sofosbuvir-based treatment vs. Standard/Usual Care- Old standard-of-care (interferon-based therapies),Treatment-naive and treatment-experienced,Not Stated,19 Years,"Female, Male",Full,"Lifetime, 10, 20, 30 years",3.00,3.00,55378,United States,2014,60541.85
14491,Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma,"BACKGROUND: Phase 3 randomized trials have shown that maintenance rituximab (MR) therapy or radioimmunotherapy (RIT) consolidation following frontline therapy can improve progression-free survival for patients with follicular lymphoma (FL), but the cost-effectiveness of these approaches with respect to observation has not been examined using a common modeling framework. OBJECTIVES: To evaluate and compare the economic impact of MR and RIT consolidation versus observation, respectively, following the first-line induction therapy for patients with advanced-stage FL. METHODS: We developed Markov models to estimate patients' lifetime costs, quality-adjusted life-years (QALYs), and life-years (LYs) after MR, RIT, and observation following frontline FL treatment from the US payer's perspective. Progression risks, adverse event probabilities, costs, and utilities were estimated from clinical data of Primary RItuximab and MAintenance (PRIMA) trial, Eastern Cooperative Oncology Group (ECOG) trial (for MR), and First-line Indolent Trial (for RIT) and the published literature. We evaluated the incremental cost-effectiveness ratio for direct comparisons between MR/RIT and observation. Model robustness was addressed by one-way and probabilistic sensitivity analyses. RESULTS: Compared with observation, MR provided an additional 1.089 QALYs (1.099 LYs) and 1.399 QALYs (1.391 LYs) on the basis of the PRIMA trial and the ECOG trial, respectively, and RIT provided an additional 1.026 QALYs (1.034 LYs). The incremental cost per QALY gained was $40,335 (PRIMA) or $37,412 (ECOG) for MR and $40,851 for RIT. MR and RIT had comparable incremental QALYs before first progression, whereas RIT had higher incremental costs of adverse events due to higher incidences of cytopenias. CONCLUSIONS: MR and RIT following frontline FL therapy demonstrated favorable and similar cost-effectiveness profiles. The model results should be interpreted within the specific clinical settings of each trial. Selection of MR, RIT, or observation should be based on patient characteristics and expected trade-offs for these alternatives.",2015-01-18517,25773554,Value Health,Qiushi Chen,2015,18 / 2,189-97,Yes,25773554,"Qiushi Chen; Turgay Ayer; Loretta J Nastoupil; Adam C Rose; Christopher R Flowers; Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma, Value Health, 2015 Mar; 18(2):1098-3015; 189-97",QALY,United States of America,Not Stated,Not Stated,Rituximab maintenance (MR) therapy vs. Observation following frontline treatment,Not Stated,Not Stated,19 Years,"Female, Male",Full,"Lifetime, 72 months",3.00,3.00,40335,United States,2013,44811.45
14492,Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma,"BACKGROUND: Phase 3 randomized trials have shown that maintenance rituximab (MR) therapy or radioimmunotherapy (RIT) consolidation following frontline therapy can improve progression-free survival for patients with follicular lymphoma (FL), but the cost-effectiveness of these approaches with respect to observation has not been examined using a common modeling framework. OBJECTIVES: To evaluate and compare the economic impact of MR and RIT consolidation versus observation, respectively, following the first-line induction therapy for patients with advanced-stage FL. METHODS: We developed Markov models to estimate patients' lifetime costs, quality-adjusted life-years (QALYs), and life-years (LYs) after MR, RIT, and observation following frontline FL treatment from the US payer's perspective. Progression risks, adverse event probabilities, costs, and utilities were estimated from clinical data of Primary RItuximab and MAintenance (PRIMA) trial, Eastern Cooperative Oncology Group (ECOG) trial (for MR), and First-line Indolent Trial (for RIT) and the published literature. We evaluated the incremental cost-effectiveness ratio for direct comparisons between MR/RIT and observation. Model robustness was addressed by one-way and probabilistic sensitivity analyses. RESULTS: Compared with observation, MR provided an additional 1.089 QALYs (1.099 LYs) and 1.399 QALYs (1.391 LYs) on the basis of the PRIMA trial and the ECOG trial, respectively, and RIT provided an additional 1.026 QALYs (1.034 LYs). The incremental cost per QALY gained was $40,335 (PRIMA) or $37,412 (ECOG) for MR and $40,851 for RIT. MR and RIT had comparable incremental QALYs before first progression, whereas RIT had higher incremental costs of adverse events due to higher incidences of cytopenias. CONCLUSIONS: MR and RIT following frontline FL therapy demonstrated favorable and similar cost-effectiveness profiles. The model results should be interpreted within the specific clinical settings of each trial. Selection of MR, RIT, or observation should be based on patient characteristics and expected trade-offs for these alternatives.",2015-01-18517,25773554,Value Health,Qiushi Chen,2015,18 / 2,189-97,Yes,25773554,"Qiushi Chen; Turgay Ayer; Loretta J Nastoupil; Adam C Rose; Christopher R Flowers; Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma, Value Health, 2015 Mar; 18(2):1098-3015; 189-97",QALY,United States of America,Not Stated,Not Stated,Radio-immunotherapy (RIT) consolidation vs. Observation following frontline treatment,Not Stated,Not Stated,19 Years,"Female, Male",Full,"Lifetime, 72 months",3.00,3.00,40851,United States,2013,45384.72
14493,Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma,"BACKGROUND: Phase 3 randomized trials have shown that maintenance rituximab (MR) therapy or radioimmunotherapy (RIT) consolidation following frontline therapy can improve progression-free survival for patients with follicular lymphoma (FL), but the cost-effectiveness of these approaches with respect to observation has not been examined using a common modeling framework. OBJECTIVES: To evaluate and compare the economic impact of MR and RIT consolidation versus observation, respectively, following the first-line induction therapy for patients with advanced-stage FL. METHODS: We developed Markov models to estimate patients' lifetime costs, quality-adjusted life-years (QALYs), and life-years (LYs) after MR, RIT, and observation following frontline FL treatment from the US payer's perspective. Progression risks, adverse event probabilities, costs, and utilities were estimated from clinical data of Primary RItuximab and MAintenance (PRIMA) trial, Eastern Cooperative Oncology Group (ECOG) trial (for MR), and First-line Indolent Trial (for RIT) and the published literature. We evaluated the incremental cost-effectiveness ratio for direct comparisons between MR/RIT and observation. Model robustness was addressed by one-way and probabilistic sensitivity analyses. RESULTS: Compared with observation, MR provided an additional 1.089 QALYs (1.099 LYs) and 1.399 QALYs (1.391 LYs) on the basis of the PRIMA trial and the ECOG trial, respectively, and RIT provided an additional 1.026 QALYs (1.034 LYs). The incremental cost per QALY gained was $40,335 (PRIMA) or $37,412 (ECOG) for MR and $40,851 for RIT. MR and RIT had comparable incremental QALYs before first progression, whereas RIT had higher incremental costs of adverse events due to higher incidences of cytopenias. CONCLUSIONS: MR and RIT following frontline FL therapy demonstrated favorable and similar cost-effectiveness profiles. The model results should be interpreted within the specific clinical settings of each trial. Selection of MR, RIT, or observation should be based on patient characteristics and expected trade-offs for these alternatives.",2015-01-18517,25773554,Value Health,Qiushi Chen,2015,18 / 2,189-97,Yes,25773554,"Qiushi Chen; Turgay Ayer; Loretta J Nastoupil; Adam C Rose; Christopher R Flowers; Comparing the cost-effectiveness of rituximab maintenance and radioimmunotherapy consolidation versus observation following first-line therapy in patients with follicular lymphoma, Value Health, 2015 Mar; 18(2):1098-3015; 189-97",QALY,United States of America,Not Stated,Not Stated,"Rituximab maintenance (MR) therapy, 375 mg/m2 once per week for 4 weeks every 6 months for 2 year vs. Observation following frontline treatment",Not Stated,Not Stated,19 Years,"Female, Male",Full,"Lifetime, 72 months",3.00,3.00,37412,United States,2013,41564.05
14494,Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis,"OBJECTIVES: To estimate the cost-effectiveness of tocilizumab (TCZ) monotherapy (Mono) versus adalimumab (ADA) Mono from the US payer perspective in patients with rheumatoid arthritis for whom methotrexate is inappropriate. METHODS: We compared TCZ Mono (8 mg/kg monthly) with ADA Mono (40 mg every other week), using efficacy results from a head-to-head study, ADalimumab ACTemrA (ADACTA). We calculated the incremental cost per responder (achievement of American College of Rheumatology [ACR] 20% improvement criteria, ACR 50% improvement criteria, ACR 70% improvement criteria, or low disease activity score) for TCZ versus ADA at 6 months. A patient-level simulation was used to estimate the lifetime incremental cost per quality-adjusted life-year (QALY) of initiating treatment with TCZ Mono versus ADA Mono. Both drugs are followed by an etanercept-certolizumab-palliative care sequence. Nonresponders discontinue at 6 months; responders experience a constant probability of discontinuation. Discontinuers move to the next treatment. ACR responses produce changes in the Health Assessment Questionnaire (HAQ) score. We mapped the HAQ score to utility to estimate QALYs. Costs include those related to hospitalization and those related to treatment (drug acquisition, administration, and monitoring). Probabilistic and one-way sensitivity analyses were conducted, along with several scenario analyses. RESULTS: Compared with ADA, TCZ was more effective, with an estimated 6-month incremental cost ranging from $6,570 per additional low disease activity score achiever to $14,265 per additional ACR 70% improvement criteria responder. The lifetime incremental cost-effectiveness ratio was $36,944/QALY. CONCLUSIONS: TCZ Mono is projected to be cost-effective compared with ADA Mono in patients with severe rheumatoid arthritis for whom methotrexate is not appropriate, from a US payer perspective.",2015-01-18519,25773552,Value Health,Josh J Carlson,2015,18 / 2,173-9,Yes,25773552,"Josh J Carlson; Sarika Ogale; Fred Dejonckheere; Sean D Sullivan; Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis, Value Health, 2015 Mar; 18(2):1098-3015; 173-9",QALY,United States of America,Not Stated,Not Stated,"Tocilizumab monotherapy, 8 mg/kg every other week, intravenously vs. Adalimumab monotherapy, 40 mg every other week, subcutaneously",Not Stated,Not Stated,19 Years,"Female, Male",Full,"6 Months, Lifetime",3.00,3.00,36944,United States,2013,41044.11
14495,Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis,"OBJECTIVES: To estimate the cost-effectiveness of tocilizumab (TCZ) monotherapy (Mono) versus adalimumab (ADA) Mono from the US payer perspective in patients with rheumatoid arthritis for whom methotrexate is inappropriate. METHODS: We compared TCZ Mono (8 mg/kg monthly) with ADA Mono (40 mg every other week), using efficacy results from a head-to-head study, ADalimumab ACTemrA (ADACTA). We calculated the incremental cost per responder (achievement of American College of Rheumatology [ACR] 20% improvement criteria, ACR 50% improvement criteria, ACR 70% improvement criteria, or low disease activity score) for TCZ versus ADA at 6 months. A patient-level simulation was used to estimate the lifetime incremental cost per quality-adjusted life-year (QALY) of initiating treatment with TCZ Mono versus ADA Mono. Both drugs are followed by an etanercept-certolizumab-palliative care sequence. Nonresponders discontinue at 6 months; responders experience a constant probability of discontinuation. Discontinuers move to the next treatment. ACR responses produce changes in the Health Assessment Questionnaire (HAQ) score. We mapped the HAQ score to utility to estimate QALYs. Costs include those related to hospitalization and those related to treatment (drug acquisition, administration, and monitoring). Probabilistic and one-way sensitivity analyses were conducted, along with several scenario analyses. RESULTS: Compared with ADA, TCZ was more effective, with an estimated 6-month incremental cost ranging from $6,570 per additional low disease activity score achiever to $14,265 per additional ACR 70% improvement criteria responder. The lifetime incremental cost-effectiveness ratio was $36,944/QALY. CONCLUSIONS: TCZ Mono is projected to be cost-effective compared with ADA Mono in patients with severe rheumatoid arthritis for whom methotrexate is not appropriate, from a US payer perspective.",2015-01-18519,25773552,Value Health,Josh J Carlson,2015,18 / 2,173-9,Yes,25773552,"Josh J Carlson; Sarika Ogale; Fred Dejonckheere; Sean D Sullivan; Economic evaluation of tocilizumab monotherapy compared to adalimumab monotherapy in the treatment of severe active rheumatoid arthritis, Value Health, 2015 Mar; 18(2):1098-3015; 173-9",QALY,United States of America,Not Stated,Not Stated,"Tocilizumab monotherapy, 8 mg/kg weekly, intravenously vs. Adalimumab monotherapy, 40 mg weekly, subcutaneously",Not Stated,Not Stated,19 Years,"Female, Male",Full,"6 Months, Lifetime",3.00,3.00,-705833.31,United States,2013,-784168
14496,An economic analysis of adherence engineering to improve use of best practices during central line maintenance procedures,"OBJECTIVE: Adherence engineering applies human factors principles to examine non-adherence within a specific task and to guide the development of materials or equipment to increase protocol adherence and reduce human error. Central line maintenance (CLM) for intensive care unit (ICU) patients is a task through which error or non-adherence to protocols can cause central line-associated bloodstream infections (CLABSIs). We conducted an economic analysis of an adherence engineering CLM kit designed to improve the CLM task and reduce the risk of CLABSI. METHODS: We constructed a Markov model to compare the cost-effectiveness of the CLM kit, which contains each of the 27 items necessary for performing the CLM procedure, compared with the standard care procedure for CLM, in which each item for dressing maintenance is gathered separately. We estimated the model using the cost of CLABSI overall ($45,685) as well as the excess LOS (6.9 excess ICU days, 3.5 excess general ward days). RESULTS: Assuming the CLM kit reduces the risk of CLABSI by 100% and 50%, this strategy was less costly (cost savings between $306 and $860) and more effective (between 0.05 and 0.13 more quality-adjusted life-years) compared with not using the pre-packaged kit. We identified threshold values for the effectiveness of the kit in reducing CLABSI for which the kit strategy was no longer less costly. CONCLUSION: An adherence engineering-based intervention to streamline the CLM process can improve patient outcomes and lower costs. Patient safety can be improved by adopting new approaches that are based on human factors principles.",2015-01-18520,25772996,Infect Control Hosp Epidemiol,Richard E Nelson,2015,36 / 5,550-6,No,25772996,"Richard E Nelson; Aaron W Angelovic; Scott D Nelson; Jeremy R Gleed; Frank A Drews; An economic analysis of adherence engineering to improve use of best practices during central line maintenance procedures, Infect Control Hosp Epidemiol, 2015 May; 36(5):0899-823X; 550-6",QALY,United States of America,Not Stated,Not Stated,Central line maintenance kit vs. None,Not Stated,45 Years,45 Years,"Female, Male",Full,Lifetime,Not Stated,3.00,-6615.38,United States,2013,-7349.57
14497,An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine,"BACKGROUND: New vaccine technologies may improve the acceptability, delivery (potentially enabling self-administration), and product efficacy of influenza vaccines. One such technology is the microneedle patch (MNP), a skin delivery technology currently in development. Although MNPs hold promise in preclinical studies, their potential economic and epidemiologic impacts have not yet been evaluated. METHODS: We utilized a susceptible-exposed-infectious-recovered (SEIR) transmission model linked to an economic influenza outcomes model to assess the economic value of introducing the MNP into the current influenza vaccine market in the United States from the third-party payer and societal perspectives. We also explored the impact of different vaccination settings, self-administration, the MNP price, vaccine efficacy, compliance, and MNP market share. Outcomes included costs, quality-adjusted life years (QALYs), cases, and incremental cost-effectiveness ratios (ICERs; cost/QALY). RESULTS: With healthcare provider administration, MNP introduction would be cost-effective (ICERs </=$23,347/QALY) at all MNP price points ($9.50-$30) and market shares (10-60%) assessed, except when compliance and efficacy were assumed to be the same as existing vaccines and the MNP occupied a 10% market share. If MNP self-administration were available (assuming the same efficacy as current technologies), MNP compliance or its efficacy would need to increase by >/=3% in order to be cost-effective (ICERs </=$1401/QALY), assuming a 2% reduction in administration success with unsupervised self-administration. Under these conditions, MNP introduction would be cost-effective for all price points and market shares assessed. CONCLUSIONS: When healthcare providers administered the MNP, its introduction would be cost-effective or dominant (i.e., less costly and more effective) in the majority of scenarios assessed. If self-administration were available, MNP introduction would be cost-effective if it increased compliance enough to overcome any decrease in self-administration success or if the MNP presentation afforded an increase in efficacy over current delivery methods for influenza vaccines.",2015-01-18521,25772675,Vaccine,Bruce Y Lee,2015,33 / 37,4727-36,Yes,25772675,"Bruce Y Lee; Sarah M Bartsch; Mercy Mvundura; Courtney Jarrahian; Kristina M Zapf; Kathleen Marinan; Angela R Wateska; Bill Snyder; Savitha Swaminathan; Erica Jacoby; James J Norman; Mark R Prausnitz; Darin Zehrung; An economic model assessing the value of microneedle patch delivery of the seasonal influenza vaccine, Vaccine, 2015 Sep 8; 33(37):1873-2518; 4727-36",QALY,United States of America,Not Stated,Not Stated,Microneedle patch delivery of the seasonal influenza vaccine vs. Standard/Usual Care,Not Stated,Not Stated,19 Years,"Female, Male",Full,Lifetime,3.00,3.00,182,United States,2013,202.2
14498,Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy,"Multiple sclerosis (MS) is a chronic progressive disease that carries a high socioeconomic burden. Spasticity (rigidity and spasms) is common in MS and contributes to MS-related disability. This study aims to evaluate the cost-effectiveness of Sativex((R)) (9-delta-tetrahydrocannabinol plus cannabidiol oromucosal spray) when used as add-on therapy for management of resistant MS-related spasticity in the context of the Italian healthcare system. A previously published Markov model-based analysis for the German and Spanish context was replicated, adapting it to the Italian setting. Model parameters were updated to reflect recent findings about MS-related spasticity and use of Sativex in daily clinical practice. The base case incremental cost-effectiveness ratio for Sativex use in Italy over a 5-year period was estimated to be euro4968 per quality-adjusted life-year gained (year of costing: 2013). Sativex remained an efficient option in the Italian healthcare context - below the commonly accepted incremental threshold of euro30,000 per quality-adjusted life-year gained - when deterministic and probabilistic sensitivity analyses were conducted. Sativex can be regarded as a cost-effective treatment option for patients with MS-related spasticity in Italy.",2015-01-18522,25771713,Expert Rev Pharmacoecon Outcomes Res,John Slof,2015,15 / 3,379-91,No,25771713,"John Slof; Leonardo Ruiz; Carlos Vila; Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy, Expert Rev Pharmacoecon Outcomes Res, 2015 Jun; 15(3):1744-8379; 379-91",QALY,Italy,Not Stated,Not Stated,Sativex vs. Standard/Usual Care,Not Stated,48.6 Years,48.6 Years,"Female, Male",Full,5 Years,3.00,3.00,4968,Euro,2013,7330.48
14499,Platelet-Rich Plasma Reduces Retear Rates After Arthroscopic Repair of Small- and Medium-Sized Rotator Cuff Tears but Is Not Cost-Effective,"BACKGROUND: It has been suggested that platelet-rich plasma (PRP) improves healing after arthroscopic rotator cuff repair. The current literature provides ample but inconsistent data on this topic. PURPOSE: To systematically review the current in vivo evidence for the use of platelet concentrates (PRP) in the arthroscopic treatment of rotator cuff tears to assess effectiveness, safety, and cost-effectiveness. STUDY DESIGN: Meta-analysis and cost-effectiveness analysis. METHODS: Published evidence from controlled, human trials of rotator cuff repair augmented with platelet concentrates was systematically gathered, and data on retear rates were extracted. Mathematical and clinical heterogeneity was evaluated, and fixed-effect meta-analysis was performed to calculate the risk ratio (RR) of retears and the number needed to treat (NNT). Subgroup analyses were made for small/medium tears (n = 404) and large/massive tears (n = 374). Cost-effectiveness was assessed using data from this meta-analysis and using cost data from the literature, including extensive sensitivity analyses, to calculate the incremental cost-effectiveness ratio (ICER). RESULTS: Thirteen studies published between 2010 and 2014 were identified for analysis. The RR for retear for all patients was 0.87 (95% CI, 0.67-1.12; P = .286). For small- and medium-sized tears (<3 cm), the RR for retear was 0.60 (95% CI, 0.37-0.97), consistent with a significant difference in favor of PRP use (P = .038). This translated into an NNT of 14 (95% CI, 7-125). However, at an ICER of US$127,893 per quality-adjusted life year gained, assuming a 5% revision rate, the use of PRP was not cost-effective for small- and medium-sized tears. CONCLUSION: In large tears, even with double-row repair, the beneficial effects of PRP alone are insufficient to compensate the progressed tissue damage. The study data suggest that PRP may promote healing of small- and medium-sized tears to reduce retear rates. However, despite the substantial biological effect, at current cost, the use of PRP is not cost-effective in arthroscopic repair of small- and medium-sized tears.",2015-01-18532,25767267,Am J Sports Med,Patrick Vavken,2015,/,,No,25767267,"Patrick Vavken; Patrick Sadoghi; Matthew Palmer; Claudio Rosso; Andreas M Mueller; Gregor Szoelloesy; Victor Valderrabano; Platelet-Rich Plasma Reduces Retear Rates After Arthroscopic Repair of Small- and Medium-Sized Rotator Cuff Tears but Is Not Cost-Effective, Am J Sports Med, 2015 Apr 30; ():1552-3365",QALY,United States of America,Not Stated,Not Stated,"Platelet concentrates (platelet-rich plasma, PRP) vs. None",Not Stated,Not Stated,Not Stated,"Female, Male",Full,2 Years,Not Stated,Not Stated,141355.92,United States,2013,157043.86
14500,A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer,"OBJECTIVE: To evaluate the cost-effectiveness of bevacizumab in recurrent/persistent and metastatic cervical cancer using recently reported updated survival and toxicology data. METHODS: A Markov decision tree based on the Gynecologic Oncology Group 240 randomized trial was created. The 2013 MediCare Services Drug Payment Table and Physician Fee Schedule provided costs. In the 5-year model subjects transitioned through the following states: response, progression, minor complications, severe complications, and death. Patients experiencing a health utility per month according to treatment effectiveness were calculated. Because cervical cancer survival is measured in months rather than years, results were reported in both quality adjusted cervical cancer life months and years (QALmonth, QALY), adjusted from a baseline of having advanced cervical cancer during a month. RESULTS: The estimated total cost of therapy with bevacizumab is approximately 13.2 times that for chemotherapy alone, adding $73,791 per 3.5months (0.29year) of life gained, resulting in an incremental cost-effectiveness ratio (ICER) of $21.083 per month of added life. The ICER increased to $5775 per month of added life and $24,597/QALmonth ($295,164/QALY) due to the smaller difference in QALmonths. With 75% bevacizumab cost reduction, the ICER is $6737/QALmonth ($80,844/QALY), which translates to $23,580 for the 3.5month (0.29year) gain in OS. CONCLUSIONS: Increased costs are primarily related to the cost of drug and not the management of bevacizumab-induced complications. Cost reductions in bevacizumab result in dramatic declines in the ICER, suggesting that cost reconciliation in advanced cervical cancer may be possible through the availability of biosimilars, and/or less expensive, equally efficacious anti-angiogenesis agents.",2015-01-18538,25766118,Gynecol Oncol,Lindsey E Minion,2015,137 / 3,490-6,No,25766118,"Lindsey E Minion; Jiaru Bai; Bradley J Monk; L Robin Keller; Eskander N Ramez; Gareth K Forde; John K Chan; Krishnansu S Tewari; A Markov model to evaluate cost-effectiveness of antiangiogenesis therapy using bevacizumab in advanced cervical cancer, Gynecol Oncol, 2015 Jun; 137(3):0090-8258; 490-6",QALY,United States of America,Not Stated,Not Stated,Antiangiogenesis therapy with bevacizumab vs. Standard/Usual Care- Chemotherapy alone (cisplatin + paclitaxel),"Untreated, recurrent/persistent and metastatic cervical cancer",Not Stated,19 Years,Female,Full,5 Years,Not Stated,Not Stated,252996,United States,2013,281073.97
